[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7446
31. Bunyapaiboonsri T, Yoiprommarat S, Khonsanit A, Komwijit S: Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J Nat Prod; 2008 May;71(5):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
  • New phenolic mono- and digalactopyranosides (1 and 2), their aglycone KS-501a (3), and a new phenolic 4-O-methylglucopyranoside (4) were isolated from the filamentous fungus Acremonium sp. BCC 14080.
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Screening Assays, Antitumor. Humans. Hydroxybenzoates / chemistry. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / pharmacology. Inhibitory Concentration 50. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363379.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glycosides; 0 / Hydroxybenzoates; 0 / Phenols; 120634-86-8 / KS 501
  •  go-up   go-down


32. Higgins HJ, Voutsalath M, Holland JM: Muir-torre syndrome: a case report. J Clin Aesthet Dermatol; 2009 Aug;2(8):30-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muir-torre syndrome: a case report.
  • Muir-Torre syndrome is an autosomal dominant genodermatosis associated with sebaceous neoplasms and visceral malignancies.
  • Characteristic sebaceous neoplasms include sebaceous adenoma, sebaceous carcinoma, sebaceoma, and keratoacanthoma with sebaceous differentiation.
  • The clinical and histological features of a patient with Muir-Torre syndrome who had two sebaceous adenomas, multiple basal cell carcinomas, and frontal bossing in association with colon cancer are presented in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):79-89 [7712655.001]
  • [Cites] Cutis. 2005 Mar;75(3):149-55 [15839358.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Am J Dermatopathol. 2006 Feb;28(1):56-9 [16456327.001]
  • [Cites] World J Surg Oncol. 2006;4:8 [16466577.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1039-42 [16924054.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):608-10 [18308310.001]
  • [Cites] Cutis. 2008 Oct;82(4):252-6 [19055168.001]
  • [Cites] Dermatol Ther. 2008 Nov-Dec;21(6):459-66 [19076624.001]
  • (PMID = 20729952.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923964
  •  go-up   go-down


33. Kamat G, Yelikar B, Shettar S, Karigoudar MH: Pigmented trichoblastoma with sebaceous hyperplasia. Indian J Dermatol Venereol Leprol; 2009 Sep-Oct;75(5):506-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastoma is a rare benign trichogenic tumour with epithelial and mesenchymal components recapitulating the germinal hair bulb and associated mesenchyme.
  • Microscopy of tumour revealed nodular tumour spanning the entire dermis with collection of mesenchymal cells resembling follicular papilla.
  • There is a need for differentiation of this tumor which is benign, from other pigmented tumors having basaloid arrangement of cells such as basal cell carcinoma.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / diagnosis. Sebaceous Gland Neoplasms / diagnosis
  • [MeSH-minor] Humans. Hyperplasia. Male. Middle Aged. Skin Neoplasms / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736433.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3
Advertisement
4. Fryer SL, Frank LR, Spadoni AD, Theilmann RJ, Nagel BJ, Schweinsburg AD, Tapert SF: Microstructural integrity of the corpus callosum linked with neuropsychological performance in adolescents. Brain Cogn; 2008 Jul;67(2):225-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microstructural integrity of the corpus callosum linked with neuropsychological performance in adolescents.
  • Fractional anisotropy (FA) and mean diffusion (MD) were evaluated within the splenium and body of the corpus callosum in relation to cognitive performance.
  • RESULTS: Visuospatial construction abilities were associated with white matter integrity in both the splenium and body of the corpus callosum, while only splenium integrity was associated with language and psychomotor function.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Oct;229(1):44-50 [12920176.001]
  • [Cites] Neuron. 2000 Feb;25(2):493-500 [10719902.001]
  • [Cites] J Cogn Neurosci. 2004 Sep;16(7):1227-33 [15453975.001]
  • [Cites] Neuropsychology. 2004 Oct;18(4):629-37 [15506830.001]
  • [Cites] Neuropsychologia. 1971 Mar;9(1):97-113 [5146491.001]
  • [Cites] Percept Mot Skills. 1977 Apr;44(2):367-73 [866038.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):578-91 [4056827.001]
  • [Cites] Brain. 1989 Feb;112 ( Pt 1):165-75 [2645017.001]
  • [Cites] Addict Behav. 1989;14(3):291-300 [2787585.001]
  • [Cites] Neuroradiology. 1992;34(5):370-80 [1407513.001]
  • [Cites] Brain Res. 1992 Dec 11;598(1-2):143-53 [1486477.001]
  • [Cites] Ann Neurol. 1993 Jul;34(1):71-5 [8517683.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):28-38 [10638065.001]
  • [Cites] Comput Biomed Res. 1996 Jun;29(3):162-73 [8812068.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Aug;24(8):1214-21 [10968660.001]
  • [Cites] Brain. 2000 Dec;123 Pt 12:2501-11 [11099451.001]
  • [Cites] Brain Res Bull. 2001 Feb;54(3):255-66 [11287130.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):443-9 [11314570.001]
  • [Cites] Magn Reson Med. 2001 Jun;45(6):935-9 [11378869.001]
  • [Cites] Radiology. 2002 Jan;222(1):212-8 [11756728.001]
  • [Cites] Neuroimage. 2002 Mar;15(3):708-18 [11848714.001]
  • [Cites] NMR Biomed. 1997 Jun-Aug;10(4-5):171-8 [9430344.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1999 May;23(4):571-88 [10390717.001]
  • [Cites] J Magn Reson Imaging. 2005 May;21(5):503-11 [15834918.001]
  • [Cites] Neuroimage. 2005 Jul 15;26(4):1164-73 [15961051.001]
  • [Cites] Drug Alcohol Depend. 2005 Aug 1;79(2):201-10 [16002029.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Jul;29(7):1214-22 [16046877.001]
  • [Cites] Hum Brain Mapp. 2005 Oct;26(2):139-47 [15858815.001]
  • [Cites] Neuropsychol Rev. 2005 Jun;15(2):59-71 [16211466.001]
  • [Cites] Biophys J. 2005 Nov;89(5):2927-38 [16100258.001]
  • [Cites] Cereb Cortex. 2005 Dec;15(12):1848-54 [15758200.001]
  • [Cites] Cereb Cortex. 2006 Apr;16(4):553-60 [16033925.001]
  • [Cites] Neurobiol Aging. 2006 Jul;27(7):994-1009 [15964101.001]
  • [Cites] Neuroreport. 2006 Sep 18;17(13):1427-31 [16932152.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):213-23 [17242625.001]
  • [Cites] J Child Psychol Psychiatry. 2007 Jun;48(6):592-600 [17537075.001]
  • [Cites] Psychol Bull. 1992 Jul;112(1):155-9 [19565683.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1083-99 [12111955.001]
  • [Cites] Brain Cogn. 2002 Dec;50(3):396-413 [12480486.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Dec;26(12):1863-71 [12500111.001]
  • [Cites] Biophys J. 1994 Jan;66(1):259-67 [8130344.001]
  • [Cites] J Magn Reson B. 1994 Mar;103(3):247-54 [8019776.001]
  • [Cites] Arch Neurol. 1995 Jan;52(1):32-8 [7826273.001]
  • [Cites] Neuropsychologia. 1995 Aug;33(8):923-36 [8524454.001]
  • [Cites] J Magn Reson B. 1996 Jun;111(3):209-19 [8661285.001]
  • [Cites] Biol Psychiatry. 2004 Feb 1;55(3):323-6 [14744477.001]
  • (PMID = 18346830.001).
  • [ISSN] 1090-2147
  • [Journal-full-title] Brain and cognition
  • [ISO-abbreviation] Brain Cogn
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH064729; United States / NIDA NIH HHS / DA / R21 DA015228; United States / NIAAA NIH HHS / AA / R01 AA013419; United States / NIAAA NIH HHS / AA / T32 AA013525; United States / NIDA NIH HHS / DA / DA15228; United States / NIAAA NIH HHS / AA / AA13419; United States / NIDA NIH HHS / DA / DA021182; United States / NIDA NIH HHS / DA / R01 DA021182-01; United States / NIMH NIH HHS / MH / MH064729; United States / NIDA NIH HHS / DA / R01 DA021182
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS55792; NLM/ PMC2491343
  •  go-up   go-down


35. Dutta A, Bhattacharya M, Barat P, Mukherjee P, Gayathri N, Das GC: Lattice resistance to dislocation motion at the nanoscale. Phys Rev Lett; 2008 Sep 12;101(11):115506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this Letter, we propose a model that demonstrates the effect of a free surface on the lattice resistance experienced by a moving dislocation in nanodimensional systems.
  • To verify this finding, molecular dynamics simulations for an edge dislocation in bcc molybdenum are performed, and the results are found to be in agreement with the numerical implementations of this model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Phys Rev Lett. 2010 Aug 27;105(9):099601; author reply 099602 [20868200.001]
  • (PMID = 18851298.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Limtong S, Yongmanitchai W: Candida chanthaburiensis sp. nov., Candida kungkrabaensis sp. nov. and Candida suratensis sp. nov., three novel yeast species from decaying plant materials submerged in water of mangrove forests. Antonie Van Leeuwenhoek; 2010 Oct;98(3):379-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were named as Candida chanthaburiensis sp. nov. (type strain EM33(T) = BCC 23057(T) = NBRC 102176(T) = CBS 10926(T)), Candida kungkrabaensis sp. nov. (type strain EM40(T) = BCC 23060(T) = NBRC 102179(T) = CBS 10927(T)), and Candida suratensis sp. nov. (type strain SM56(T) = BCC 25961(T) = NBRC 103858(T) = CBS 10928(T)).

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467812.001).
  • [ISSN] 1572-9699
  • [Journal-full-title] Antonie van Leeuwenhoek
  • [ISO-abbreviation] Antonie Van Leeuwenhoek
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal; 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


37. Mills O, Thomas LB: Basaloid follicular hamartoma. Arch Pathol Lab Med; 2010 Aug;134(8):1215-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basaloid follicular hamartoma is a benign lesion of important consideration because it can be mistaken both clinically and histologically for basal cell carcinoma.
  • The formation of basaloid follicular hamartoma has been linked to a mutation in the patched gene, which is part of the same pathway implicated in nevoid basal cell carcinoma syndrome.
  • While these hamartomas are considered benign lesions, malignant growths have been reported to arise within them, which raises the question, "Is basaloid follicular hamartoma a premalignant lesion?
  • " Correct identification allows for periodic monitoring for malignant transformation, while sparing patients unnecessary surgery.
  • Treatment strategies, including experimental therapies, are reviewed.
  • [MeSH-major] Hair Diseases / diagnosis. Hair Follicle / pathology. Hamartoma / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Mutation. Receptors, Cell Surface / genetics. Skin Neoplasms / diagnosis


38. Broberg K, Huynh E, Schläwicke Engström K, Björk J, Albin M, Ingvar C, Olsson H, Höglund M: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer; 2009;9:140
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study.
  • BACKGROUND: Mutations altering BLM function are associated with highly elevated cancer susceptibility (Bloom syndrome).
  • Thus, genetic variants of BLM and proteins that form complexes with BLM, such as TOP3A and RMI1, might affect cancer risk as well.
  • METHODS: In this study we have studied 26 tagged single nucleotide polymorphisms (tagSNPs) in RMI1, TOP3A, and BLM and their associations with cancer risk in acute myeloid leukemia/myelodysplatic syndromes (AML/MDS; N = 152), malignant melanoma (N = 170), and bladder cancer (N = 61).
  • RESULTS: Based on consistency in effect estimates for the three cancer forms and similar allelic frequencies of the variant alleles in the control groups, two SNPs in TOP3A (rs1563634 and rs12945597) and two SNPs in BLM (rs401549 and rs2532105) were selected for analysis in breast cancer cases (N = 200) and a control group recruited from spouses of cancer patients (N = 131).
  • The rs12945597 in TOP3A and rs2532105 in BLM showed increased risk for breast cancer.
  • We then combined all cases (N = 584) and controls (N = 406) respectively and found significantly increased risk for variant carriers of rs1563634 A/G (AG carriers OR = 1.7 [95%CI 1.1-2.6], AA carriers OR = 1.8 [1.2-2.8]), rs12945597 G/A (GA carriers OR = 1.5 [1.1-1.9], AA carriers OR = 1.6 [1.0-2.5]), and rs2532105 C/T (CT+TT carriers OR = 1.8 [1.4-2.5]).
  • CONCLUSION: These results further support a role of low-penetrance genes involved in BLM-associated homologous recombination for cancer risk.
  • [MeSH-major] Carrier Proteins / genetics. DNA Topoisomerases, Type I / genetics. Genetic Predisposition to Disease. Neoplasms / genetics. Nuclear Proteins / genetics. Polymorphism, Single Nucleotide. RecQ Helicases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. European Continental Ancestry Group / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5612-6 [11059748.001]
  • [Cites] Pharmacogenetics. 2000 Mar;10(2):115-22 [10761999.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3417-26 [12724401.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7657-62 [14633686.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):870-4 [14685245.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2675-80 [15102670.001]
  • [Cites] Nat Rev Genet. 2004 Jun;5(6):446-55 [15153997.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):109-16 [15287023.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):901-4 [15386379.001]
  • [Cites] Mutat Res. 1992 Apr;266(2):189-96 [1373828.001]
  • [Cites] Medicine (Baltimore). 1993 Nov;72(6):393-406 [8231788.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1465-76 [15775963.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):611-8 [15924337.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9152-4 [16230371.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W621-5 [16845085.001]
  • [Cites] Am J Epidemiol. 2006 Aug 15;164(4):297-302 [16707649.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1655-60 [16501249.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22839-46 [16766518.001]
  • [Cites] Eur J Hum Genet. 2006 Oct;14(10):1136-44 [16791138.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3916-8 [16902145.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2448-54 [16774934.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jan 19;352(3):763-8 [17141189.001]
  • [Cites] J Med Genet. 2007 Jan;44(1):e61 [17209131.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1514-20 [17495976.001]
  • [Cites] EMBO J. 2007 Jul 25;26(14):3397-409 [17599064.001]
  • [Cites] Biomarkers. 2007 Sep-Oct;12(5):523-32 [17701750.001]
  • [Cites] Carcinogenesis. 2007 Aug;28(8):1788-93 [17557904.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1523-8 [17761709.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):38-44 [17900800.001]
  • [Cites] Trends Biochem Sci. 2007 Dec;32(12):538-46 [17980605.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65 [18086758.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D825-9 [18086700.001]
  • [Cites] Leukemia. 2008 Feb;22(2):265-72 [18033323.001]
  • [Cites] Am J Gastroenterol. 2008 Feb;103(2):360-7 [17986315.001]
  • [Cites] Am J Epidemiol. 2002 Jul 15;156(2):95-109 [12117698.001]
  • (PMID = 19432957.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / RMI1 protein, human; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.4.12 / RecQ Helicases; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / DNA topoisomerase III
  • [Other-IDs] NLM/ PMC2685436
  •  go-up   go-down


39. Blokhuis MM, Goldberg PA, Pietersen GE, Algar U, Vorster AA, Govender D, Ramesar RS: The extracolonic cancer spectrum in females with the common 'South African' hMLH1 c.C1528T mutation. Fam Cancer; 2008;7(3):191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extracolonic cancer spectrum in females with the common 'South African' hMLH1 c.C1528T mutation.
  • Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disease, characterized by the occurrence of predominantly colon and endometrial cancer and, less frequently, cancer of the small bowel, stomach, hepatobiliary tract, ureter, renal pelvis, ovaries and brain.
  • The aim of this study was to investigate the frequency of extracolonic cancers in a cohort of females sharing the same c.C1528T disease-predisposing mutation in the hMLH1 gene.
  • Data on cancer history were obtained from 87 mutation-positive females and 121 mutation-negative sisters, as a control group.
  • Testing for microsatellite instability (MSI) and expression of the wild-type hMLH1 allele was performed on extra-colonic tumour tissue blocks of mutation-positive individuals.
  • Extracolonic cancer occurred in 14% (12/87) of mutation-positive females vs. 7% (8/121) of mutation-negative females (P = 0.10).
  • Breast cancer, which was the most frequent extra-colonic cancer in mutation positive females (53%), occurred at a young age, and occurred bilaterally in two out of seven cases.
  • Involvement of the hMLH1 gene was confirmed in five out of seven cases of breast cancer, two cases of endometrial cancer, one case of ovarian cancer and one case of renal cell carcinoma, by detecting immunohistochemical compromise of the gene product.
  • Although the study might not have been adequately statistically powered (to provide a significant P value), the noteworthy findings in this study include the confirmation of a range of Lynch II type cancers in a cohort we previously thought was wholly predisposed to Lynch I features, and a confirmation of breast cancer as part of the spectrum of Lynch syndrome cancers affecting women.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Mutation. Neoplasms / epidemiology. Neoplasms / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adult. Alleles. Case-Control Studies. Cohort Studies. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cysteine. Female. Genetic Predisposition to Disease. Humans. Incidence. Microsatellite Instability. Middle Aged. MutL Protein Homolog 1. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Multiple Primary / genetics. Phenotype. Population Surveillance. Risk Factors. Sex Factors. Siblings. South Africa / epidemiology. Threonine

  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2001 Jun;68(6):1533-5 [11359214.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Nat Genet. 1997 Oct;17 (2):135-6 [9326924.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1223-32 [12352241.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):372-7 [3366037.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Mar;101(2):123-7 [9494613.001]
  • [Cites] Fam Cancer. 2005;4(3):245-8 [16136385.001]
  • [Cites] Mutat Res. 2006 Dec 1;602(1-2):175-81 [17087981.001]
  • [Cites] Ann Intern Med. 1984 May;100(5):700-1 [6712034.001]
  • [Cites] Fam Cancer. 2001;1(1):9-15 [14574010.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1322-6 [16311127.001]
  • [Cites] Breast. 2003 Dec;12(6):351-6 [14659104.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):530-6 [12496483.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):261-9 [16421367.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):118-127 [11112663.001]
  • [Cites] Cancer. 2001 May 1;91(9):1724-31 [11335897.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):516-9 [10404064.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4545-9 [11389088.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4285-92 [16908935.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4570-3 [15837976.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1014-9 [11861375.001]
  • [Cites] BMC Cancer. 2005 Mar 01;5:23 [15740628.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1250-3; discussion 1253-5 [9788388.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):428-33 [9559626.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1148-9 [12615735.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1507-17 [17003399.001]
  • [Cites] S Afr Med J. 2000 Jul;90(7):709-14 [10985134.001]
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):897-9 [11844809.001]
  • [Cites] Eur J Hum Genet. 2006 Apr;14(4):390-402 [16479259.001]
  • [Cites] Cancer. 1996 May 1;77(9):1836-43 [8646682.001]
  • [Cites] Colorectal Dis. 2007 Jul;9(6):509-14 [17477847.001]
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] J Med Genet. 2007 Jan;44(1):10-15 [17079251.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] J Med Genet. 2003 Mar;40(3):208-13 [12624141.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):87-91 [10206076.001]
  • [Cites] Fam Cancer. 2005;4(3):249-54 [16136386.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Fam Cancer. 2004;3(1):41-7 [15131405.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):74-80 [14529665.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4074-80 [11600610.001]
  • [Cites] Am J Hum Genet. 1997 Jul;61(1):129-38 [9245993.001]
  • (PMID = 18049911.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 2ZD004190S / Threonine; EC 3.6.1.3 / MutL Protein Homolog 1; K848JZ4886 / Cysteine
  •  go-up   go-down


40. Pylkäs K, Tommiska J, Syrjäkoski K, Kere J, Gatei M, Waddell N, Allinen M, Karppinen SM, Rapakko K, Kääriäinen H, Aittomäki K, Blomqvist C, Mustonen A, Holli K, Khanna KK, Kallioniemi OP, Nevanlinna H, Winqvist R: Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis; 2007 May;28(5):1040-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
  • Studies on A-T families have shown that obligate female carriers have increased risk of developing breast cancer.
  • Here we have evaluated the role of known Finnish ATM germ line mutations as possible breast cancer predisposing alleles outside A-T families by analyzing their prevalence in large cohorts of familial and unselected breast cancer cases.
  • Of seven different alterations, two were observed in the studied breast cancer material.
  • ATM 6903insA (causing protein truncation) was seen in 3/541 familial and 5/1124 unselected cases, but not among healthy population controls (0/1107).
  • 7570G>C (Ala2524Pro) occurred in 1/541 familial and 2/1124 unselected cases compared with 1/1107 in controls.
  • Additionally, 8734A>G (Arg2912Gly) associated previously with breast cancer susceptibility and suggested to be causative also for A-T was detected in 2/541 of familial cases, but not in unselected cases (0/1124) or controls (0/1107).
  • In total, heterozygous ATM mutation carriers were observed in 6/541 familial [P = 0.006, odds ratio (OR) 12.4, 95% confidence interval (CI) 1.5-103.3) and 7/1124 unselected cases (P = 0.07, OR 6.9, 95% CI 0.9-56.4), compared with 1/1107 in controls, suggesting an apparent yet overall limited contribution to predisposition to cancer.
  • Interestingly, results from functional analysis of the breast cancer-associated ATM mutations indicated that cancer susceptibility is not restricted to mutations with dominant-negative effect on kinase activity, displayed only by 7570G>C, whereas 8734A>G showed only a partial defect in the phosphorylation of ATM substrates, and 6903insA seemed to be a null allele.
  • [MeSH-major] Ataxia Telangiectasia / genetics. Breast Neoplasms / genetics. Cell Cycle Proteins / physiology. DNA-Binding Proteins / physiology. Genetic Predisposition to Disease. Mutation. Protein-Serine-Threonine Kinases / physiology. Tumor Suppressor Proteins / physiology


41. Tassone P, Blotta S, Palmieri C, Masciari S, Quaresima B, Montagna M, D'Andrea E, Eramo OP, Migale L, Costanzo F, Tagliaferri P, Venuta S: Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol; 2005 May;26(5):1257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
  • Germ-line mutations in the breast cancer susceptibility BRCA1 gene account for approximately half of hereditary breast cancer cases and most of breast/ovarian cancer cases.
  • We speculated whether breast hereditary cancers might be differentially sensitive to antitumor agents such as the mitotic spindle poisons Vinca alcaloid vinorelbine (VNR) and the taxoid docetaxel (DOC), which are commonly used in the treatment of breast cancer.
  • We investigated the sensitivity of the BRCA1-mutated HCC1937 (derived from a BRCA1 related hereditary tumor) and BRCA1 competent MCF-7 and MDA-MB468 sporadic breast cancer cell lines to these drugs.
  • Instead, BRCA1-mutated breast cancer cells exposed to DOC showed similar sensitivity as compared to BRCA1-competent MCF-7 or were less sensitive than MDA-MB468.
  • Moreover, VNR induced apoptotic cell death and cytoskeletal rearrangements in HCC1937 cells.
  • We further investigated whether a defective targeting of mitotic spindle by the mutated BRCA1 gene product might be involved in the differential sensitivity to VNR.
  • In conclusion, our data suggest that BRCA1-mutated tumors might be differentially sensitive to anti-microtubule agents, supporting the rationale for clinical trials to improve the outcome of hereditary breast cancer patients by tailored treatments.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / genetics. Genes, BRCA1. Taxoids / pharmacology. Vinblastine / analogs & derivatives. Vinblastine / pharmacology
  • [MeSH-minor] Apoptosis. Cytoskeleton / pathology. DNA Mutational Analysis. Drug Resistance, Neoplasm. Female. Germ-Line Mutation. Humans. Microtubules / pathology. Spindle Apparatus / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809716.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


42. Anehosur V: Gorlin's syndrome - Report of a case and management of cystic lesions. J Maxillofac Oral Surg; 2009 Jun;8(2):184-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gorlin's syndrome - Report of a case and management of cystic lesions.
  • It is characterized by cutaneous basal cell carcinomas, multiple keratocysts in the jaw bones and skeletal anomalies.
  • A case is presented with multiple odontogenic keratocyst and dentigerous cysts occurring in all quadrants of oral cavity with features suggestive of Gorlin's Syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1991 Apr;99(4):294-7 [2008888.001]
  • [Cites] Br J Oral Maxillofac Surg. 1988 Jun;26(3):215-20 [2456095.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Aug;47(8):870-3 [2664107.001]
  • [Cites] Ned Tijdschr Tandheelkd. 1988 Apr;95(4):123-6 [3269490.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] J Prosthet Dent. 1995 May;73(5):405-10 [7658387.001]
  • [Cites] J Am Acad Dermatol. 1993 Jul;29(1):34-41 [8315076.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] J Periodontol. 1997 Mar;68(3):306-11 [9100207.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • [Cites] Int J Oral Maxillofac Surg. 1999 Jun;28(3):216-23 [10355946.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):80-2 [11289627.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Jul;59(7):720-5; discussion 726-7 [11429726.001]
  • [Cites] AMA Arch Derm. 1959 Jan;79(1):67-77; discussion 77-80 [13605278.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Mar;33(2):117-24 [15050066.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):660-4 [15583537.001]
  • (PMID = 23139503.001).
  • [ISSN] 0972-8279
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453930
  • [Keywords] NOTNLM ; Carcinoma / Dentigerous cyst / Keratocyst / Nevoid
  •  go-up   go-down


43. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon-Margalit R, Friedlander Y, Paltiel O, Harlap S: Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study. Breast Cancer Res Treat; 2008 Mar;108(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study.
  • Gestational diabetes is becoming increasingly common; it is important to determine how it relates to future risk of disease.
  • We investigated the relation of gestational diabetes to breast cancer in 37,926 women who had one or more live births in 1964-1976 for whom information had been collected on complications of pregnancy.
  • In this cohort there were 1,626 cases of breast cancer reported to the Israel Cancer Registry before January 1, 2005 and 410 cases of gestational diabetes recorded from birth records.
  • There were 29 cases of breast cancer among women diagnosed with gestational diabetes.
  • Using Cox proportional hazards models to control for age and birth order at the first observed birth and other characteristics, we found that the incidence of breast cancer was increased among women diagnosed with gestational diabetes (relative rate = 1.5, 95% confidence interval 1.0-2.1).
  • The findings suggest that gestational diabetes may be an important early marker of breast cancer risk among post-menopausal women, but these results need to be confirmed in future studies.
  • [MeSH-major] Breast Neoplasms / epidemiology. Diabetes, Gestational / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17476589.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 80197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual histological variants of prostatic carcinoma: clinical significance.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • These variants are rare and account for 5-10% of carcinomas that originate in the prostate.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-major] Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


45. Tallón-Walton V, Nieminen P, Arte S, Ustrell-Torrent JM, Carvalho-Lobato P, Manzanares-Céspedes MC: Oral findings in Midline Syndrome: a case report and literature review. Med Oral Patol Oral Cir Bucal; 2010 Jul;15(4):e579-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral findings in Midline Syndrome: a case report and literature review.
  • The patient presents agenesis of the corpus callosum, encephalocele, iris coloboma, hypertelorism, submucosal cleft palate and dental anomalies.
  • [MeSH-major] Agenesis of Corpus Callosum. Cleft Palate. Coloboma. Encephalocele. Hypertelorism. Iris / abnormalities. Tooth Abnormalities
  • [MeSH-minor] Abnormalities, Multiple / diagnosis. Child. Female. Humans. Phenotype. Syndrome

  • MedlinePlus Health Information. consumer health - Cleft Lip and Palate.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173721.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  •  go-up   go-down


51. de Feraudy S, Boubakour-Azzouz I, Fraitag S, Berneburg M, Chan L, Chew K, Clericuzio CL, Cunningham B, Tope WD, Cleaver JE: Diagnosing xeroderma pigmentosum group C by immunohistochemistry. Am J Dermatopathol; 2010 Apr;32(2):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine whether immunohistochemistry (IHC) would be a robust alternative method to diagnose patients with XPC, we stained sections of paraffin-embedded skin biopsies for XPC by IHC, using 69 archived blocks from confirmed or clinically suspect patients with XPA, XPC, XPD, XPE, and without XP.
  • We found that XPC expression was strong in all skin biopsies from patients without (14 of 14) and other patients with XP (4 of 4), whereas XPC expression was lost in all biopsies from confirmed XPC patients (29 of 29).
  • Patches of strong XPC signal could be detected in sun-damaged skin, squamous and basal cell carcinomas from patients with XPC that colocalized with strong expression of p53 and Ki-67.
  • Patients with XPC can therefore be diagnosed by IHC from paraffin-embedded skin biopsies from regions of skin that are without sun damage or sun-induced tumors.
  • This fast and inexpensive method should increase the options for the diagnosis of patients with XPC from paraffin-embedded skin biopsies and could be developed for other complementation groups.
  • [MeSH-major] Immunohistochemistry / methods. Xeroderma Pigmentosum / classification. Xeroderma Pigmentosum / diagnosis
  • [MeSH-minor] Biopsy. DNA-Binding Proteins / metabolism. Humans. Ki-67 Antigen / metabolism. Lymphocytes / metabolism. Lymphocytes / pathology. Paraffin Embedding. Skin / metabolism. Skin / pathology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • Genetic Alliance. consumer health - Xeroderma pigmentosum, group C.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19915453.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R01NS052781; United States / NIAMS NIH HHS / AR / P01 AR050440
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 156533-34-5 / XPC protein, human
  •  go-up   go-down


52. Salas A, Vega A, Milne RL, García-Magariños M, Ruibal A, Benítez J, Carracedo A: The 'Pokemon' (ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer. Clin Med Oncol; 2008;2:357-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 'Pokemon' (ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer.
  • It has been proposed that the excess of familiar risk associated with breast cancer could be explained by the cumulative effect of multiple weakly predisposing alleles.
  • Here we aimed to determine whether polymorphisms in ZBTB7 are associated with breast cancer risk in a sample of cases and controls collected in hospitals from North and Central Spanish patients.
  • We genotyped 15 SNPs in ZBTB7, including the flanking regions, with an average coverage of 1 SNP/2.4 Kb, in 360 sporadic breast cancer cases and 402 controls.
  • Comparison of allele, genotype and haplotype frequencies between cases and controls did not reveal associations using Pearson's chi-square test and a permutation procedure to correct for multiple test.
  • In this, the first study of the ZBTB7 gene in relation to, sporadic breast cancer, we found no evidence of an association.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9420-7 [17018596.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):623-5; author reply 624 [18199560.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Nature. 2005 Jan 20;433(7023):278-85 [15662416.001]
  • [Cites] Radiat Res. 2005 Jun;163(6):698-9 [16044499.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5898-905 [16998504.001]
  • [Cites] Bioinformatics. 2000 Feb;16(2):182-3 [10842743.001]
  • [Cites] Genet Epidemiol. 2003 Sep;25(2):115-21 [12916020.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):221-36 [15557796.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] PLoS Genet. 2007 Mar 16;3(3):e42 [17367212.001]
  • (PMID = 21892298.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161631
  • [Keywords] NOTNLM ; POKEMON / ZBTB7 / association study / breast cancer / case-control
  •  go-up   go-down


53. Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG: The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat; 2008 Dec;112(3):569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.
  • The germline CHEK2 1100delC mutation is a low penetrance breast cancer susceptibility allele, frequently observed in patient with family history of breast cancer and/or young age and the frequency varied according to race or ethnicity.
  • In this study, we evaluated the significance of CHEK2 1100delC in predisposition to breast cancer by assessing its frequency in a material of 493 Korean breast cancer patients who had been screened for BRCA1 and BRCA2 mutations (42 patients had deleterious mutation of BRCA1/2).
  • None of the 493 Korean patients with breast cancer who were candidate for BRCA1 and BRCA2 test carried the 1100delC mutation observed in Caucasians with limited frequency.
  • In the previous studies, we observed higher or comparable prevalence of BRCA1 and BRCA2 mutations in Korean patients with breast cancer compared to Caucasian breast cancer population.
  • In the present study, we evaluated the role of a CHEK2 1100delC as a susceptibility mutation of breast cancer in the Korean population.
  • However, our results suggest that this mutation is absent or may be very infrequent in Korean patients with breast cancer who have high risk of BRCA1 and BRCA2 mutation, making its screening irrelevant from the practical point view.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, BRCA1. Genes, BRCA2. Mutation. Protein-Serine-Threonine Kinases / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18175216.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


54. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • The adjacent unaffected skin showed a normal number of melanocytes and melanin pigment.
  • To our knowledge, this is the first biopsy-proven case of vitiligo in an imiquimod-treated area.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Melanocytes / pathology. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


55. Wiseman RL, Green NS, Kelly JW: Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry; 2005 Jun 28;44(25):9265-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, small molecule-mediated kinetic stabilization of the native state is an attractive strategy to prevent the misfolding and misassembly associated with TTR amyloid disease.
  • Small molecule kinetic stabilization of TTR has been established by concentration-dependent inhibition of acid-mediated amyloidogenesis and urea-induced tetramer dissociation.
  • Addition of amyloidogenesis inhibitors to this exchange reaction slows tetramer dissociation in a concentration-dependent manner, stopping dissociation at concentrations where at least one inhibitor is bound to each tetramer in solution.
  • Subunit exchange enables the rate of tetramer dissociation and the kinetic stabilization imparted by small molecule binding to be evaluated under physiological conditions in which the TTR concentration is not reduced by aggregation or irreversible dissociation.
  • [MeSH-minor] Kinetics. Molecular Structure. Protein Binding. Protein Denaturation. Protein Structure, Quaternary. Protein Subunits / antagonists & inhibitors. Protein Subunits / chemistry. Protein Subunits / genetics. Protein Subunits / metabolism. Thermodynamics

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966751.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK060304-03; United States / NIDDK NIH HHS / DK / DK46335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prealbumin; 0 / Protein Subunits
  •  go-up   go-down


56. Wettstein R, Erba P, Farhadi J, Kalbermatten DF, Arnold A, Haug M, Pierer G: Incomplete excision of basal cell carcinoma in the subunits of the nose. Scand J Plast Reconstr Surg Hand Surg; 2008;42(2):92-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma in the subunits of the nose.
  • Reconstructive procedures after resection of nasal basal cell carcinoma (BCC) vary depending on the subunit involved.
  • The aim of the present study was to assess the influence of the location of the BCC on the rate of incomplete excisions, so we made a retrospective analysis of all nasal BCC excised at our hospital between 2002 and 2005.
  • BCC were most likely to be incompletely excised on the nasal tip and alae, and both subunits required more elaborate reconstructions.
  • This, however, was not the result of poor estimation of the extent of the tumour and reluctance to excise more challenging areas widely for reconstruction, but to the method chosen to eradicate the tumour.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335353.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Ly E, Piot O, Durlach A, Bernard P, Manfait M: Differential diagnosis of cutaneous carcinomas by infrared spectral micro-imaging combined with pattern recognition. Analyst; 2009 Jun;134(6):1208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of cutaneous carcinomas by infrared spectral micro-imaging combined with pattern recognition.
  • Non-melanoma skin cancer includes basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and Bowen's disease.
  • The differential diagnosis of these lesions is sometimes difficult and relies on the histopathological examination of surgical specimens.
  • However, a precise differential diagnosis is crucial for an accurate therapy and thus better patient care.
  • FTIR spectral micro-imaging was applied directly on formalin-fixed paraffin-embedded samples of non-melanoma skin cancers.
  • High correlation was obtained between the prediction maps and the histology which proves the great potential of FTIR spectroscopy for the differential diagnosis of skin carcinomas.
  • [MeSH-major] Pattern Recognition, Automated. Skin Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Discriminant Analysis. Eccrine Glands / pathology. Hair Follicle / pathology. Humans. Image Interpretation, Computer-Assisted. Principal Component Analysis. Reproducibility of Results. Sebaceous Glands / pathology. Spectroscopy, Fourier Transform Infrared

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475150.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Ramos-Ceballos FI, Pashaei S, Kincannon JM, Morgan MB, Smoller BR: Bcl-2, CD34 and CD10 expression in basaloid follicular hamartoma, vellus hair hamartoma and neurofollicular hamartoma demonstrate full follicular differentiation. J Cutan Pathol; 2008 May;35(5):477-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Generalized basaloid follicular hamartoma syndrome (GBFHS) is a rare, recently-described, autosomal-dominantly inherited disorder that presents with disseminated milia, palmoplantar pitting, hypotrichosis and basaloid follicular hamartomas (BFH).
  • BFH is a benign adnexal tumor that resembles basal cell carcinoma (BCC).
  • In this study, we report two cases of GBFHS and stain BFH, a vellus hair hamartoma (VHH) and a neurofollicular hamartoma (NH) with CD34, bcl-2 and CD10 to characterize and compare the staining patterns of these follicular tumors.
  • Bcl-2 stained the outermost cell layers of the basaloid nests in all specimens.
  • Bcl-2 stains the outermost cell layer of these tumors.
  • These results show the similarities in differentiation between these benign follicular neoplasms and trichoepithelioma.

  • Genetic Alliance. consumer health - Basaloid Follicular Hamartoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 May;36(5):603; author reply 604 [19476535.001]
  • (PMID = 18399809.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


59. Haanpää M, Reiman M, Nikkilä J, Erkko H, Pylkäs K, Winqvist R: Mutation analysis of the AATF gene in breast cancer families. BMC Cancer; 2009;9:457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the AATF gene in breast cancer families.
  • BACKGROUND: About 5-10% of breast cancer is due to inherited disease predisposition.
  • AATF plays an important role in the regulation of gene transcription and cell proliferation.
  • Based on its biological function, and direct interaction with several known breast cancer risk factors, AATF is a good candidate gene for being involved in heritable cancer susceptibility.
  • METHODS: Here we have screened the entire coding region of AATF in affected index cases from 121 Finnish cancer families for germline defects, using conformation sensitive gel electrophoresis and direct sequencing.
  • Based on the in silico analyses of these sequence alterations, as well as their occurrence in cases and controls, none of them, however, were predicted to be pathogenic.
  • CONCLUSIONS: To our knowledge, this is the first study reporting the mutation screening of the AATF gene in familial breast cancer cases.
  • No evidence for the association with breast cancer was observed.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Breast Neoplasms / genetics. Family. Repressor Proteins / genetics
  • [MeSH-minor] DNA Mutational Analysis. Female. Finland. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Mutation, Missense. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Mar 15;446(7133):316-9 [17287723.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):215-20 [17006618.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):17-22 [18163131.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3292-300 [18084323.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2008;9:321-45 [18544032.001]
  • [Cites] Oncogene. 2009 Apr 23;28(16):1843-52 [19305427.001]
  • [Cites] FASEB J. 2000 May;14(7):904-12 [10783144.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 24;276(2):660-6 [11027528.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1301-8 [11044354.001]
  • [Cites] Dev Biol. 2000 Nov 15;227(2):324-42 [11071758.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):116-9 [11139324.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):209-12 [11461078.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):387-99 [12450794.001]
  • [Cites] Hum Genet. 2003 Apr;112(4):434-5 [12574941.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36496-504 [12847090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1681-5 [9465076.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1544-8 [9585608.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):943-9 [10359546.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1305-20 [15933754.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1593-9 [16474176.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):473-86 [17157788.001]
  • [Cites] Biochem Cell Biol. 2007 Aug;85(4):477-83 [17713582.001]
  • (PMID = 20025740.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AATF protein, human; 0 / Apoptosis Regulatory Proteins; 0 / Repressor Proteins
  • [Other-IDs] NLM/ PMC2806411
  •  go-up   go-down


60. Güth U, Huang DJ, Schötzau A, Dirnhofer S, Wight E, Singer G: Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification. Breast; 2010 Feb;19(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification.
  • We evaluated 166 breast cancer cases with non-inflammatory skin involvement (NISI), which were classified in the TNM classification as T4b.
  • The distribution of tumour sizes and stages was: < or =3 cm:24.1%, 3.1-5 cm:21.7%, 5.1-10 cm:33.1%, >10 cm:21.1%; stages:I/II:21.0%, III:43.4%, IV:35.6%.
  • According to the inherent rules of tumour classification, only tumours with similar morphologic extent and prognostic significance should be combined.
  • Since there is a high grade of heterogeneity, this basic tenet is clearly violated regarding breast cancer with NISI.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / pathology. Neoplasm Staging / classification. Skin Neoplasms / classification. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Switzerland. Women's Health


61. Maskarinec G, Erber E, Verheus M, Hernandez BY, Killeen J, Cashin S, Cline JM: Soy consumption and histopathologic markers in breast tissue using tissue microarrays. Nutr Cancer; 2009;61(5):708-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy consumption and histopathologic markers in breast tissue using tissue microarrays.
  • This study examined the relation of soy intake with hormonal and proliferation markers in benign and malignant breast tissue using tissue microarrays (TMAs).
  • TMAs with up to 4 malignant and 4 benign tissue samples for 268 breast cancer cases were constructed.
  • The TMAs were stained for estrogen receptor (ER) alpha, ERbeta, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), proliferating cell nuclear antigen (PCNA), and Ki-67 using standard immunohistochemical methods.
  • A higher percentage of women showed positive marker expression in malignant than in benign tissue.
  • Early life soy intake was associated with lower HER2/neu and PCNA staining of malignant tissue.
  • In benign tissue, early life soy intake showed higher ER and PR expression, but no difference in proliferation markers.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4017-24 [10566643.001]
  • [Cites] Eur J Nutr. 2008 Apr;47(3):138-44 [18427855.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):17-37 [10963618.001]
  • [Cites] J Pathol. 2000 Dec;192(4):549-53 [11113875.001]
  • [Cites] Environ Health Perspect. 2000 Aug;108(8):701-8 [10964789.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):394-403 [11207158.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):483-8 [11352858.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3095S-108S [11694655.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):67-76 [12160087.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1491-6 [12189192.001]
  • [Cites] Oncologist. 2003;8(4):307-25 [12897328.001]
  • [Cites] Endocrinology. 1988 Mar;122(3):935-44 [3342760.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):416-9 [1350788.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):785-94 [8896889.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4252-63 [9751507.001]
  • [Cites] Am J Clin Nutr. 1998 Dec;68(6 Suppl):1431S-1435S [9848512.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2520-5 [10051675.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):89-97 [15615919.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):275-81 [15791572.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):812-20 [16084952.001]
  • [Cites] Am J Epidemiol. 2005 Oct 15;162(8):743-52 [16150892.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):459-71 [16595782.001]
  • [Cites] Fertil Steril. 2006 Apr;85 Suppl 1:1179-86 [16616090.001]
  • [Cites] Diagn Mol Pathol. 2006 Sep;15(3):157-61 [16932071.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1275-84 [16985246.001]
  • [Cites] J Pathol. 2007 Apr;211(5):499-506 [17236182.001]
  • [Cites] J Clin Pathol. 2007 Apr;60(4):397-404 [16775123.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):45-9 [17536306.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):9-14 [18182974.001]
  • [Cites] BMC Cancer. 2008;8:36 [18237383.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8 [18812550.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(1):189-96 [18256926.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • (PMID = 19838945.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085265-03; United States / NCI NIH HHS / CA / R21 CA100250; United States / NCI NIH HHS / CA / R21 CA1080250; United States / NCI NIH HHS / CA / CA108250-02; United States / NCI NIH HHS / CA / R21 CA108250; United States / NCI NIH HHS / CA / R01 CA85265; United States / NCI NIH HHS / CA / CA085265-03; United States / NCI NIH HHS / CA / R37 CA054281-17; United States / NCI NIH HHS / CA / R01 CA085265; United States / NCI NIH HHS / CA / CA054281-17; United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CA / R37 CA 54281; United States / NCI NIH HHS / CA / R21 CA108250-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS215718; NLM/ PMC2903450
  •  go-up   go-down


62. Monroe KR, Murphy SP, Kolonel LN, Pike MC: Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. Br J Cancer; 2007 Aug 6;97(3):440-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study.
  • There is evidence that grapefruit, an inhibitor of CYP3A4, increases plasma oestrogen concentrations.
  • Since it is well established that oestrogen is associated with breast cancer risk, it is plausible that regular intake of grapefruit would increase a woman's risk of breast cancer.
  • We investigated the association of grapefruit intake with breast cancer risk in the Hawaii-Los Angeles Multiethnic Cohort Study, a prospective cohort that includes over 50 000 postmenopausal women from five racial/ethnic groups.
  • A total of 1657 incident breast cancer cases were available for analysis.
  • Grapefruit intake was significantly associated with an increased risk of breast cancer (relative risk=1.30, 95% confidence interval 1.06-1.58) for subjects in the highest category of intake, that is, one-quarter grapefruit or more per day, compared to non-consumers (P(trend)=0.015).
  • Grapefruit intake may increase the risk of breast cancer among postmenopausal women.

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2005 Jun;112(6):692-5 [15924521.001]
  • [Cites] Analyst. 1994 Jul;119(7):1497-509 [7943740.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1285-91 [16170777.001]
  • [Cites] JAMA. 2006 Feb 8;295(6):629-42 [16467232.001]
  • [Cites] Nutr Cancer. 2007;58(2):127-35 [17640158.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1458-65 [16204695.001]
  • [Cites] JAMA. 2000 Jan 26;283(4):485-91 [10659874.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):358-70 [10695594.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] CMAJ. 2002 Aug 6;167(3):279-80 [12186177.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Maturitas. 1994 Dec;20(2-3):155-63 [7715468.001]
  • [Cites] Br J Clin Pharmacol. 1995 Aug;40(2):135-40 [8562295.001]
  • [Cites] Eur J Clin Pharmacol. 1995;49(1-2):61-7 [8751023.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2545-53 [9153299.001]
  • [Cites] Eur J Clin Pharmacol. 1997;52(2):139-45 [9174684.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:1-17 [10331074.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):183-93 [15644545.001]
  • [Cites] Obstet Gynecol. 2005 Feb;105(2):429-31 [15684175.001]
  • [Cites] J Clin Pharmacol. 2003 Aug;43(8):831-9 [12953340.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):1-9 [14679360.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2379-87 [15197199.001]
  • [Cites] Am J Cardiovasc Drugs. 2004;4(5):281-97 [15449971.001]
  • [Cites] N Engl J Med. 1982 Dec 16;307(25):1542-7 [7144835.001]
  • [Cites] J Assoc Off Anal Chem. 1985 Jul-Aug;68(4):677-9 [2993226.001]
  • [Cites] Nutr Cancer. 1986;8(2):141-7 [3010251.001]
  • [Cites] Am J Clin Nutr. 1986 Dec;44(6):945-53 [3024478.001]
  • [Cites] Clin Invest Med. 1989 Dec;12(6):357-62 [2612087.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1990;201:3-23 [2173856.001]
  • [Cites] Lancet. 1991 Feb 2;337(8736):268-9 [1671113.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991 May;38(5):621-8 [1645589.001]
  • [Cites] Eur J Clin Pharmacol. 1992;42(3):313-7 [1577050.001]
  • [Cites] Clin Pharmacol Ther. 1993 Jun;53(6):637-42 [8513655.001]
  • [CommentIn] Br J Cancer. 2008 Jan 15;98(1):240-1 [18026192.001]
  • (PMID = 17622247.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA054281; United States / NCI NIH HHS / CA / R37 CA54281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Other-IDs] NLM/ PMC2360312
  •  go-up   go-down


63. Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Jan;14(1):20-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of male breast cancer.
  • Breast cancer in men is a rare disease, accounting for approximately 1% of all breast cancer cases.
  • Although the epidemiologic literature regarding female breast cancer is extensive, relatively little is known about the etiology of male breast cancer (MBC).
  • This review is intended to summarize the existing body of evidence on genetic and epidemiologic risk factors for breast cancer in men.
  • Overall, the epidemiology of MBC presents similarities with the epidemiology of female breast cancer.
  • Major genetic factors associated with an increased risk of breast cancer for men include BRCA2 mutations, which are believed to account for the majority of inherited breast cancer in men, Klinefelter syndrome, and a positive family history.
  • Suspected epidemiologic risk factors include prostate cancer,prostate cancer treatment, gynecomastia, occupational exposures (e.g., electromagnetic fields, polycyclic aromatic hydrocarbons, and high temperatures), dietary factors (e.g., meat intake and fruit and vegetable consumption), and alcohol intake.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology
  • [MeSH-minor] Biomarkers, Tumor. Diet. Environmental Exposure. Estrogens / metabolism. Genes, BRCA2. Genetic Predisposition to Disease. Gynecomastia / complications. Humans. Klinefelter Syndrome / genetics. Male. Mutation. Risk Factors. Testicular Diseases / complications

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668471.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens
  • [Number-of-references] 126
  •  go-up   go-down


64. El Demellawy D, Escott N, Salama S, Alowami S: Sebaceoma of the external ear canal: an unusual location. Case report and review of the literature. J Cutan Pathol; 2008 Oct;35(10):963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceoma of the external ear canal: an unusual location. Case report and review of the literature.
  • Sebaceous neoplasms of the external ear canal are extremely rare.
  • Only two cases of sebaceous neoplasms have been reported in the English literature, a sebaceous carcinoma and a sebaceous adenoma.
  • We report a case of sebaceoma of the external ear canal.
  • We highlight the differential diagnosis, particularly sebaceous carcinoma and basal cell carcinoma with sebaceous differentiation.
  • Awareness of the possible occurrence of sebaceoma in the auditory canal may prevent the diagnostic pitfall of misidentifying this tumor.
  • [MeSH-major] Ear Canal / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564279.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


65. Ducic Y, Marra DE, Kennard C: Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck. Laryngoscope; 2009 Apr;119(4):774-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck.
  • OBJECTIVE: To review our experience with Mohs excision of massive cutaneous carcinomas for peripheral margin control, followed by planned definitive resection of the deeply invasive component of the carcinoma.
  • METHODS: All cases of massive (at least 10 cm in dimension) cutaneous carcinomas treated by the technique outlined by Yadranko Ducic from 1998-2006.
  • RESULTS: A total of 28 cases (7 squamous cell carcinomas, 14 basal cell carcinomas, 7 basosquamous carcinomas) were treated in this manner.
  • Average maximal tumor dimension was 12.7 cm with a range of 10-21 cm.
  • There were a total of 7 local recurrences (5 squamous cell carcinoma and 2 basal cell carcinoma).
  • CONCLUSIONS: The technique appears to be an excellent means of treatment of massive, neglected, and deeply invasive cutaneous carcinomas of the face and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Basosquamous / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205010.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Decara JM, Aguilera J, Abdala R, Sánchez P, Figueroa FL, Herrera E: Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin. Exp Dermatol; 2008 Oct;17(10):806-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin.
  • This immunomodulation has been recognized as an important factor related to skin cancer development.
  • This is the first time that UCA isomers have been measured in epidermis of skin biopsies from patients with squamous cell carcinoma (SCC) and with basal cell carcinoma (BCC) and compared with the tumor periphery and biopsies of healthy photoexposed and non-photoexposed skin as controls.
  • Analysis of UCA in healthy skin showed significant increase in total UCA content in non-photoexposed body sites compared with highly exposed skins.
  • In contrast, the percentage of cUCA was higher in photoexposed body sites.
  • No differences were found in total UCA concentration between the tumor samples and healthy photoexposed skin.
  • Higher levels of cUCA were detected in SCC biopsies (44% of total UCA) compared with samples of BCC and that of healthy photoexposed skin (30%).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Epidermis / radiation effects. Skin Neoplasms / pathology. Ultraviolet Rays. Urocanic Acid / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312386.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] G8D26XJJ3B / Urocanic Acid
  •  go-up   go-down


67. Salehi Z, Mashayekhi F, Shahosseini F: Significance of eIF4E expression in skin squamous cell carcinoma. Cell Biol Int; 2007 Nov;31(11):1400-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of eIF4E expression in skin squamous cell carcinoma.
  • Cutaneous squamous cell carcinoma (SCC) is a malignant tumour of keratinising epidermal cells.
  • This type of skin cancer is the second leading cause of death after melanoma, and it is the second most common type of non-melanoma skin cancer after basal cell carcinoma.
  • The cellular and molecular events involved in the progression of skin cancers are largely unknown.
  • Translational control is critical for the proper regulation of the cell cycle, tissue induction and growth.
  • Eukaryotic initiation factor eIF4E, an important regulator of translation, plays critical roles in neo-plastic transformation and cancer progression.
  • We investigated eIF4E expression in 49 skin samples (six normal tissues, eight Bowen diseases, seven stage I, 10 stage II, 13 stage III and five stage IV SCCs).
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Eukaryotic Initiation Factor-4E / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Iran. Skin / metabolism


68. Gapska P, Scott RJ, Serrano-Fernandez P, Huzarski T, Byrski T, Kładny J, Gronwald J, Górski B, Cybulski C, Lubinski J, Debniak T: Vitamin D receptor variants and breast cancer risk in the Polish population. Breast Cancer Res Treat; 2009 Jun;115(3):629-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D receptor variants and breast cancer risk in the Polish population.
  • The aim of the study was to determine whether four VDR gene single nucleotide polymorphisms (SNPs: rs1544410, rs731236, rs10735810 and rs4516035) are associated with breast cancer risk in Polish population.
  • Two independent series of female patients were employed: 960 consecutive breast cancer cases, and 800 unselected early onset cases diagnosed under the age of 51.
  • The control group for the consecutive breast cancer cases consisted of 960 healthy, age-matched women with a negative cancer family history.
  • 550 healthy women, aged 51 or less, with negative cancer family history were selected as the independent controls for the early onset breast cancer cases.
  • The frequencies of the VDR polymorphisms in the unselected cases when compared to the respective control population failed to reveal any association between the individual SNPs and disease.
  • Examination of the group of early-onset patients, revealed an association between rs10735810 and increased breast cancer risk.
  • The remaining three examined SNPs failed to show any association with disease risk.
  • In summary, this study has identified an association between the VDR gene and early onset breast cancer risk in the Polish population.
  • [MeSH-major] Breast Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Receptors, Calcitriol / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Odds Ratio. Poland / epidemiology. Prognosis. Prospective Studies. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587672.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Calcitriol
  •  go-up   go-down


69. Aršavskaja J, Tekkel M, Lilleorg A, Padrik P, Metspalu A, Veidebaum T: BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hered Cancer Clin Pract; 2010 Apr 09;8(1):4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
  • We analyzed genetic data and questionnaire from 64 early-onset (< 45 y) breast cancer patients, 47 familial cases (patients with breast or ovarian cancer and a case of these cancers in the family), and 33 predictive cases (patients without breast or ovarian cancer, with a family history of such diseases) from Estonia for mutations in the BRCA1 gene.
  • A sub-set of familial cases and predictive cases were also analyzed for mutations in the BRCA2 gene.
  • RESULTS: We identified three clinically important mutations in the BRCA1 gene, including seven occurrences of the c.5382insC mutation, three of c.4154delA, and one instance of c.3881_3882delGA.
  • CONCLUSIONS: In our dataset, the overall frequency of clinically important BRCA1 mutations in early-onset patients, familial cases, and predictive testing was 7.6% (144 cases, 11 mutation carriers).
  • Pathogenic mutations were identified in 4 of the 64 early-onset breast cancer cases (6.3%).
  • In familial cases, clinically important mutations in the BRCA1 gene were found in 6 of the 47 individuals analyzed (12.8%).
  • In predictive cases, 1 clinically important mutation was detected in 33 individuals studied (3%).
  • The occurrence of clinically important mutations in BRCA2 in familial cases of breast cancer was 2 of the 16 individuals analyzed (12.5%).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1997 Jan;15(1):103-5 [8988179.001]
  • [Cites] J Med Genet. 2005 Feb;42(2):138-46 [15689452.001]
  • [Cites] Fam Cancer. 2005;4(2):77-84 [15951956.001]
  • [Cites] Biotechniques. 1989 Jul-Aug;7(7):736-44 [2483661.001]
  • [Cites] Am J Hum Genet. 1996 Feb;58(2):271-80 [8571953.001]
  • [Cites] Hum Mutat. 2001;17(1):75 [11139251.001]
  • [Cites] Am J Hum Genet. 2000 Jun;66(6):1963-8 [10788334.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Nature. 1995 Dec 21-28;378(6559):789-92 [8524414.001]
  • [Cites] Eur J Hum Genet. 2000 Oct;8(10):757-63 [11039575.001]
  • [Cites] Genet Test. 2002 Summer;6(2):119-21 [12215251.001]
  • [Cites] Bull Exp Biol Med. 2003 Sep;136(3):276-8 [14666193.001]
  • [Cites] Fam Cancer. 2007;6(3):281-6 [17333477.001]
  • [Cites] Breast Cancer Res. 2000;2(4):307-10 [11056688.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):404-13 [15887246.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23 [11504767.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1684-9 [2270482.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):509-14 [15254414.001]
  • [Cites] Am J Hum Genet. 1997 May;60(5):1013-20 [9150148.001]
  • [Cites] Hum Mol Genet. 1996 Jun;5(6):835-42 [8776600.001]
  • (PMID = 20380699.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2867795
  •  go-up   go-down


70. Cilliers D, Alanay Y, Boduroglu K, Utine E, Tunçbilek E, Clayton-Smith J: Cerebro-facio-thoracic dysplasia: expanding the phenotype. Clin Dysmorphol; 2007 Apr;16(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second patient has hypodensity of the grey matter on magnetic resonance imaging, which is the second report of this finding in cerebro-facio-thoracic dysplasia.
  • In addition, he has hypoplasia of the corpus callosum.
  • These cases illustrate the expanding phenotype of this condition, and support the hypothesis that this is an autosomal recessive condition.


71. Boger-Megiddo I, Shaw DW, Friedman SD, Sparks BF, Artru AA, Giedd JN, Dawson G, Dager SR: Corpus callosum morphometrics in young children with autism spectrum disorder. J Autism Dev Disord; 2006 Aug;36(6):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corpus callosum morphometrics in young children with autism spectrum disorder.
  • This study assessed midsagittal corpus callosum cross sectional areas in 3-4 year olds with autism spectrum disorder (ASD) compared to typically developing (TD) and developmentally delayed (DD) children.
  • ASD clinical subgroup analysis revealed greater proportional callosum reduction in the more severely affected autistic disorder (AD) than in pervasive developmental disorder-not otherwise specified (PDD-NOS) children.
  • Subregion analysis revealed widely distributed callosum differences between ASD and TD children.
  • Results could reflect decreased inter-hemispheric connectivity or cerebral enlargement due to increase in tissues less represented in the corpus callosum in ASD.
  • [MeSH-major] Autistic Disorder / diagnosis. Corpus Callosum / pathology. Image Processing, Computer-Assisted. Magnetic Resonance Imaging
  • [MeSH-minor] Analysis of Variance. Biometry. Brain / pathology. Child, Preschool. Developmental Disabilities / diagnosis. Diagnosis, Differential. Female. Humans. Male. Mathematical Computing. Reference Values. Sex Factors


72. Saedon H, Hubbard A: An unusual presentation of merkel cell carcinoma of the eyelid. Orbit; 2008;27(4):331-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of merkel cell carcinoma of the eyelid.
  • Merkel cell carcinoma is a rare primary neuroendocrine tumor occurring on any part of the body.
  • It usually presents as a firm, nontender, violaceous, or purple nodule located on areas of the body that have been exposed to sunlight.
  • Examination showed a 4 cm diameter, exophytic, ovoid skin lesion of the left lower lid.
  • Histological examination of therapeutic frozen section of the lesion and the presence of neuroendocrine marker and cytokeratin markers established the diagnosis of Merkel Cell carcinoma.
  • Merkel cell carcinoma can have an unusual presentation of a large, exophytic, oval lesion resembling a basal cell carcinoma.
  • Merkel cell carcinoma has predilection for rapid spread; hence, in a case of lid lesions, a suspicion for this diagnosis should be kept in mind.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Eyelid Neoplasms / chemistry. Eyelid Neoplasms / pathology. Eyelid Neoplasms / surgery. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716977.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


73. Buxton IL, Yokdang N, Matz RM: Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. Cancer Lett; 2010 May 28;291(2):131-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.
  • Several advances have recently expanded models of tumor growth and promoted the concept of tumor homeostasis, the hypothesis that primary tumors exert an anti-proliferative effect on both themselves and subclinical secondary metastases.
  • Recent trials indicate that the characterization of tumor growth as uncontrolled is inconsistent with animal models, clinical models, and epidemiological models.
  • There is a growing body of evidence which lends support to an updated concept of tumor growth: tumor homeostasis.
  • In the case of breast cancer, if not all metastasizing tumors, these advances suggest an inconvenient truth.
  • That is, if breast tumor cells metastasize to distant sites early in the tumorigenesis process, then removal of a breast tumor may hasten the development of its metastases.
  • We explore the heretofore unappreciated notion that nucleotides generated by tumor cells following the secretion of an ADP-kinase can promote metastasis and support angiogenesis.
  • Evidence is presented that blockade of the actions of nucleotides in the setting of newly diagnosed breast cancer may provide a useful adjunct to current anti-angiogenesis treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5090-101 [11431346.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1657-66 [11557556.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3109-15 [11748109.001]
  • [Cites] Cell Signal. 2002 Feb;14(2):93-8 [11781132.001]
  • [Cites] Proc West Pharmacol Soc. 2001;44:57-9 [11793995.001]
  • [Cites] Proc West Pharmacol Soc. 2001;44:61-3 [11793996.001]
  • [Cites] Br J Pharmacol. 2002 Jan;135(2):537-45 [11815389.001]
  • [Cites] Annu Rev Med. 2002;53:615-27 [11818492.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):569-76 [12007505.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):344-51 [11992402.001]
  • [Cites] Arch Biochem Biophys. 2002 May 1;401(1):29-37 [12054484.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):821-8 [12115483.001]
  • [Cites] Circ Res. 2002 Aug 23;91(4):292-9 [12193461.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1361-70 [12205027.001]
  • [Cites] Clin Exp Metastasis. 2002;19(6):465-76 [12405283.001]
  • [Cites] J Cardiovasc Pharmacol. 2002 Dec;40(6):841-53 [12451317.001]
  • [Cites] Mol Biol Cell. 2003 Jan;14(1):334-47 [12529448.001]
  • [Cites] Life Sci. 2003 Feb 14;72(13):1445-53 [12535713.001]
  • [Cites] Luminescence. 2003 May-Jun;18(3):173-81 [12701093.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):135-41 [12705634.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Trends Immunol. 2003 Jun;24(6):327-34 [12810109.001]
  • [Cites] J Bioenerg Biomembr. 2003 Feb;35(1):31-40 [12848339.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1040-7 [12763753.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2003 Sep;30(9):649-52 [12940883.001]
  • [Cites] Biochim Biophys Acta. 2003 Sep 2;1615(1-2):7-32 [12948585.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):708-17 [14760094.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1881-8 [14704231.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):162-7 [7388758.001]
  • [Cites] Circ Res. 1980 Dec;47(6):807-13 [6254686.001]
  • [Cites] J Biol Chem. 1986 Nov 25;261(33):15496-507 [3023320.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 May;84(9):3004-8 [3472246.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 6;80(3):200-4 [3346912.001]
  • [Cites] Cell. 1989 Feb 10;56(3):345-55 [2464438.001]
  • [Cites] Eur Heart J. 1989 Nov;10 Suppl F:15-21 [2695333.001]
  • [Cites] Ann N Y Acad Sci. 1990;603:300-10 [1981307.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Circ Res. 2005 Mar 4;96(4):467-75 [15692085.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1024-35 [15662049.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):735-42 [15841322.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Am J Health Syst Pharm. 2005 May 15;62(10):1017 [15901584.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2481-4 [15884091.001]
  • [Cites] Neoplasia. 2005 May;7(5):522-7 [15967104.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1816-27 [15951843.001]
  • [Cites] J Histochem Cytochem. 2005 Aug;53(8):997-1002 [15923371.001]
  • [Cites] Cancer Sci. 2005 Oct;96(10):653-60 [16232196.001]
  • [Cites] Br J Pharmacol. 2006 Jan;147 Suppl 1:S172-81 [16402102.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Pharmacol Rev. 2006 Mar;58(1):58-86 [16507883.001]
  • [Cites] J Pharm Pharmacol. 2006 Apr;58(4):481-7 [16597365.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(2):135-44 [16319971.001]
  • [Cites] Nature. 2006 May 25;441(7092):444-50 [16724056.001]
  • [Cites] Methods Mol Biol. 2006;341:73-87 [16799190.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):1064-73 [16936278.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] Circ Res. 2006 Nov 10;99(10):1100-8 [17038639.001]
  • [Cites] J Bioenerg Biomembr. 2006 Aug;38(3-4):151-61 [16944301.001]
  • [Cites] J Med Chem. 2007 Mar 22;50(6):1166-76 [17302398.001]
  • [Cites] J Gastrointest Surg. 2007 Feb;11(2):171-8 [17390169.001]
  • [Cites] Cell. 2007 Aug 24;130(4):691-703 [17719546.001]
  • [Cites] Am J Pathol. 2007 Oct;171(4):1395-404 [17823293.001]
  • [Cites] Curr Pharm Des. 2007;13(27):2795-809 [17897024.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):558-63 [17906452.001]
  • [Cites] Adv Exp Med Biol. 2007;608:1-22 [17993229.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1372-80 [17940513.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Dec;4(12):699-710 [18037874.001]
  • [Cites] J Cell Sci. 2007 Dec 15;120(Pt 24):4289-301 [18057028.001]
  • [Cites] Breast. 2008 Jan;17 Suppl 1:S3-8 [18279764.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):131-8 [18058029.001]
  • [Cites] J Biomech Eng. 2008 Apr;130(2):021010 [18412497.001]
  • [Cites] J Gastrointest Surg. 2008 May;12(5):900-6 [18320288.001]
  • [Cites] Clin Exp Metastasis. 2008;25(4):305-24 [17906932.001]
  • [Cites] Proc West Pharmacol Soc. 2007;50:58-60 [18605230.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):1009-86 [18626066.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):415-34 [18414993.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):730-56 [18639491.001]
  • [Cites] Rev Recent Clin Trials. 2008 Sep;3(3):212-6 [18782079.001]
  • [Cites] Clin Genitourin Cancer. 2008 Sep;6(2):79-85 [18824429.001]
  • [Cites] Recent Pat Antiinfect Drug Discov. 2009 Jun;4(2):108-13 [19519545.001]
  • [Cites] Proc West Pharmacol Soc. 2008;51:30-4 [19544670.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Handb Exp Pharmacol. 2009;(193):399-441 [19639290.001]
  • [Cites] Mol Cell Biochem. 2009 Sep;329(1-2):63-71 [19373546.001]
  • [Cites] Mol Cell Biochem. 2009 Sep;329(1-2):3-15 [19415463.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Adv Cancer Res. 2000;79:91-121 [10818678.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94 [10838264.001]
  • [Cites] Pharmacol Ther. 2000 Aug-Sep;87(2-3):161-73 [11007998.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31061-8 [10913128.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):547-53 [11058869.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):310-23 [11111826.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1202-10 [11222361.001]
  • [Cites] AACN Clin Issues. 2000 May;11(2):241-51 [11235433.001]
  • [Cites] Neuroscience. 1976 Aug;1(4):239-48 [11370511.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Apr;10(2):243-55, vii [11382585.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4851-7 [11406562.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1158-65 [9070493.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Feb;11(2):206-9 [9080143.001]
  • [Cites] Stem Cells. 1997;15(3):180-9 [9170209.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2602-5 [9205063.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20402-7 [9252347.001]
  • [Cites] FEBS Lett. 1998 Feb 20;423(2):243-8 [9512366.001]
  • [Cites] Cancer. 1998 Apr 25;84(2):109-14 [9570214.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2766-71 [9661889.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 29;251(3):811-7 [9790992.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):44-7 [9892181.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;237:97-132 [9893348.001]
  • [Cites] Leuk Lymphoma. 1998 Dec;32(1-2):19-28 [10036998.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 2):H1091-7 [10070096.001]
  • [Cites] Pathol Oncol Res. 2008 Sep;14(3):219-31 [18575829.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):730-41 [18834415.001]
  • [Cites] Am J Clin Oncol. 2008 Aug;31(4):363-8 [18845995.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1821-8 [18550576.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1941-6 [18647967.001]
  • [Cites] Trends Cell Biol. 2008 Nov;18(11):560-74 [18848450.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2311-6 [19029493.001]
  • [Cites] Clin Vaccine Immunol. 2009 Jan;16(1):43-8 [18987163.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):836-44 [19176381.001]
  • [Cites] Int J Urol. 2009 Feb;16(2):143-50 [19183233.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:2522-45 [19273217.001]
  • [Cites] Physiology (Bethesda). 2009 Apr;24:107-16 [19364913.001]
  • [Cites] Br J Cancer. 2009 May 5;100(9):1465-70 [19367276.001]
  • [Cites] Minerva Urol Nefrol. 2009 Jun;61(2):71-89 [19451890.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Oct 31;180(2):926-32 [1659406.001]
  • [Cites] Biochim Biophys Acta. 1993 Jun 6;1177(2):199-207 [7684612.001]
  • [Cites] Circ Res. 1994 Mar;74(3):401-7 [8118948.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):26-32 [8030752.001]
  • [Cites] J Pathol. 1994 Jan;172(1):27-34 [7931824.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):644-50 [7969516.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):506-16 [7707437.001]
  • [Cites] Biochim Biophys Acta. 1995 Jul 20;1268(1):73-80 [7626665.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:471-82 [7587101.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Cardiovasc Pharmacol. 1996 Jun;27(6):872-5 [8761855.001]
  • [Cites] Cardiovasc Res. 1996 Oct;32(4):687-98 [8915187.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):33116-22 [8955160.001]
  • [Cites] EXS. 1997;79:317-33 [9002225.001]
  • [Cites] Curr Top Med Chem. 2004;4(8):805-19 [15078212.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):943-54 [15161048.001]
  • [Cites] Cancer Lett. 2004 Jul 8;210(1):47-55 [15172120.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Trends Cardiovasc Med. 2004 May;14(4):138-43 [15177264.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):634-9; discussion 639-40 [15197090.001]
  • [Cites] J Pharmacol Sci. 2004 Jun;95(2):174-80 [15215641.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35679-86 [15175347.001]
  • [Cites] Am J Physiol. 1969 Oct;217(4):1009-17 [4980944.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Mol Cell Cardiol. 1974 Dec;6(6):561-6 [4444058.001]
  • [Cites] Biochim Biophys Acta. 1976 Nov 11;455(1):152-62 [990323.001]
  • [Cites] Eur J Pharmacol. 1978 Jul 1;50(1):27-38 [679974.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):381 [10201368.001]
  • [Cites] Am J Physiol. 1963 Feb;204:317-22 [13971060.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1782-6 [15477859.001]
  • [Cites] Breast Cancer Res. 2005;7(1):37-40 [15642181.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):743-50 [15701864.001]
  • (PMID = 19926395.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD053028; United States / NCI NIH HHS / CA / T32 CA009563-20; United States / NICHD NIH HHS / HD / HD053028-03; United States / NCI NIH HHS / CA / NIH T32 CA09563; United States / NICHD NIH HHS / HD / HD053028; United States / NHLBI NIH HHS / HL / R01 HL056422-05; United States / NICHD NIH HHS / HD / R01 HD053028-03; United States / NCI NIH HHS / CA / T32 CA009563; United States / NHLBI NIH HHS / HL / R01 HL056422; United States / NCI NIH HHS / CA / CA009563-20; United States / NHLBI NIH HHS / HL / HL056422-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Receptors, Purinergic P2; 8L70Q75FXE / Adenosine Triphosphate
  • [Number-of-references] 170
  • [Other-IDs] NLM/ NIHMS152718; NLM/ PMC2849889
  •  go-up   go-down


74. Ito K, Miyahara T, Goto T, Horiuchi T, Sakai K, Hongo K: Solitary metastatic cauda equina tumor from breast cancer -case report-. Neurol Med Chir (Tokyo); 2010;50(5):417-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastatic cauda equina tumor from breast cancer -case report-.
  • A 45-year-old woman presented with a rare case of metastatic cauda equina tumor from breast cancer without spinal column or brain metastasis.
  • She had undergone resection of breast cancer 4 years previously.
  • At surgery, the tumor was partially removed to preserve the nerve root function under electrophysiological monitoring.
  • The histological diagnosis was adenocarcinoma.
  • The tumor was located in the subarachnoid space, suggesting hematogenous metastasis from the breast cancer.
  • Cauda equina tumors may be relatively progressive regardless of imaging findings and clinical symptoms, so preoperative systemic investigation should be conducted, considering the possibility of metastatic tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Cauda Equina / pathology. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505303.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Stinco G, Governatori G, Mattighello P, Patrone P: Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review. J Dermatol; 2008 Mar;35(3):154-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review.
  • Rothmund-Thomson syndrome (RTS) is a rare genodermatosis characterized by early poikilodermatous skin lesions, often combined with juvenile cataracts, photosensitivity and bone defects.
  • Data in the published work indicate that there is an increased risk of RTS patients developing malignant tumors.
  • Herein, we report the multiple skin carcinomas observed in a case of RTS and review the published work on the occurrence of malignant tumors in these patients.
  • We report the case of a 63-year-old male with RTS who developed multiple cutaneous neoplasms (three basal cell carcinomas, three squamous cell carcinomas and Bowen's disease) over the previous 15 years.
  • A published work review confirmed that RTS is a genetic condition that predisposes subjects to the development of bone tumors, especially at an early age, and skin tumors at an adult age.
  • Therefore, alongside careful osteoarticular monitoring to identify a bone tumor quickly, during the life of a patient suffering from the syndrome, it is just as important to take appropriate preventive action and monitor the possible onset of skin tumors.
  • [MeSH-major] Carcinoma / etiology. Rothmund-Thomson Syndrome / complications. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Rothmund Thomson syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346259.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 67
  •  go-up   go-down


76. Formicone F, Fargnoli MC, Pisani F, Rascente M, Famulari A, Peris K: Cutaneous manifestations in Italian kidney transplant recipients. Transplant Proc; 2005 Jul-Aug;37(6):2527-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty (22%) nonmelanoma skin cancers were identified in seven (6.4%) patients, six basal cell carcinomas (BCC) in four patients, two squamous cell carcinomas (SCC) in two patients, and 11 BCCs in addition to one SCC in one patient.
  • Our results emphasize the importance of dermatologic examinations and monitoring kidney transplant recipients to obtain an early diagnosis and treatment of cutaneous manifestations.
  • [MeSH-major] Kidney Transplantation / adverse effects. Skin Diseases / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Italy. Male. Middle Aged. Mycoses / epidemiology. Postoperative Complications / classification. Postoperative Complications / epidemiology. Retrospective Studies. Skin Neoplasms / epidemiology. Virus Diseases / epidemiology


77. Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, Agarwal PN: Risk factors with breast cancer among women in Delhi. Indian J Cancer; 2009 Apr-Jun;46(2):132-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors with breast cancer among women in Delhi.
  • BACKGROUND: The incidence of breast cancer is on the rise in India, breast cancer is the second most common malignancy in Indian women.
  • AIM: The aim of this study was to find out the association of various risk factors with breast cancer among women in Delhi.
  • SETTINGS AND DESIGN: This was a case-control study in Lok Nayak Hospital, Delhi.
  • Subjects were women with breast cancer (N = 115) and age matched Control subjects (N-217) without breast cancer, attending Lok Nayak Hospital during 2006.
  • The risk factors studied were: age, parity, socioeconomic status, marital status, breast feeding, menarche, menopause, family history.
  • In this study, 69 (60%) cases and 127 (58.5%) controls were illiterate, the mean duration sum of total breast feeding for all children was 6.58 years in cases and 7.4 years in controls (OR = 1.91; 95% CI, 1.17 - 3.13) (P P P< 0.05).
  • There was a significant difference between breast cancer cases and controls in relation to place of residence, occupation, marital status, body mass index and breast feeding.
  • [MeSH-major] Breast Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Body Mass Index. Breast Feeding. Case-Control Studies. Confidence Intervals. Female. Humans. India / epidemiology. Marital Status. Middle Aged. Odds Ratio. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346647.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


78. Ha M, Mabuchi K, Sigurdson AJ, Freedman DM, Linet MS, Doody MM, Hauptmann M: Smoking cigarettes before first childbirth and risk of breast cancer. Am J Epidemiol; 2007 Jul 1;166(1):55-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking cigarettes before first childbirth and risk of breast cancer.
  • Inconsistent epidemiologic findings on cigarette smoking and female breast cancer risk may reflect insufficient assessment of smoking onset and amount relative to reproductive events.
  • To determine the risk of breast cancer associated with smoking during different periods of reproductive life, the authors evaluated 906 incident breast cancer cases in a nationwide cohort of 56,042 female US radiologic technologists (1983-1998) who responded to two questionnaire surveys.
  • After they accounted for age, birth cohort, and established breast cancer risk factors, smoking-related breast cancer risks differed by smoking during three reproductive time periods (p = 0.003), with a statistically significant 3% increase per pack-year of smoking between menarche and first childbirth (relative risk = 1.03, 95% confidence interval: 1.02, 1.05) and no significant association for smoking after first childbirth.
  • The findings from this study suggest that sensitivity of the female breast to tobacco carcinogens is increased during adolescence and early adulthood but decreases after first childbirth, when most breast tissue has terminally differentiated.
  • [MeSH-major] Breast Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426039.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


79. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol; 2009 Aug;61(2):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
  • BACKGROUND: The rate of development of further basal cell carcinoma (BCC) after first presentation is highly variable.
  • OBJECTIVE: We assessed the risks of developing a subsequent BCC in patients who developed a BCC and a squamous cell carcinoma (SCC) and compared them with patients who developed a BCC only.
  • METHODS: In all, 1040 patients who developed BCC only were compared with 140 patients who developed BCC and SCC to see whether the latter group included a high proportion of risk phenotypes (eg, male sex and fair skin).
  • We then compared the number of BCCs developing per year in the two groups (174 BCC only and 71 BCC/SCC) during a 5-year period after initial BCC presentation.
  • RESULTS: The BCC/SCC group demonstrated a significantly lower BCC/year rate than BCC only group.
  • The rate of development of further BCC during 5-year follow-up was lower in the BCC/SCC group because a smaller number of patients developed subsequent BCC and not because the same proportion of patients developed lesions but in smaller numbers.
  • After 5 years of follow-up, 51.1% of BCC and 74.6% of BCC/SCC cases were free from a subsequent BCC.
  • Logistic regression analysis corrected for age at initial presentation confirmed that patients with BCC/SCC were less likely to develop a further BCC during the 5 years after initial presentation (P = .001, odds ratio = 0.31, 95% confidence interval 0.15-0.63).
  • LIMITATIONS: Because of the large patient group and long study follow-up from the date of the index BCC or SCC, not all data were obtained.
  • Where this is the case, the number of patients for whom the information is available is provided.
  • CONCLUSIONS: Patients who develop a BCC are similar to patients who develop both a BCC and SCC, confirming the overlap of causative factors.
  • Patients who develop both a BCC and SCC are less likely to develop BCCs compared with patients who develop BCC only.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Probability. Prognosis. Risk Assessment. Sex Distribution

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481292.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Friedrich RE: Diagnosis and treatment of patients with nevoid basal cell carcinoma syndrome [Gorlin-Goltz syndrome (GGS)]. Anticancer Res; 2007 Jul-Aug;27(4A):1783-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of patients with nevoid basal cell carcinoma syndrome [Gorlin-Goltz syndrome (GGS)].
  • BACKGROUND: The nevoid basal cell carcinoma syndrome (NBCC) is a rare and autosomal dominant inherited disease with well-defined characteristics, summarized by Gorlin and Goltz in 1960.
  • In the head and neck region, cerebral calcifications, basal cell carcinoma (BCC) and multiple keratocysts of the jaws are the predominant findings.
  • Thirteen patients were also physically investigated, including X-ray diagnosis.
  • The number of patients with characteristic head and neck findings in the spectrum of NBCC varied: basal cell carcinoma (n = 15), keratocysts of the jaws (n = 13), cerebral calcification visible on plain radiographs (n = 15), palmar pits (n = 9).
  • One of these 2 patients underwent external irradiation for a BCC of the frontotemporal region.
  • Nine years later a frontal BCC had to be treated.
  • The other developed several other BCC inside and outside the irradiation field.
  • Up to 50 BCC per patient had to be resected.
  • Interdisciplinary cooperation is mandatory in the diagnosis and follow-up control of patients with NBCC.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Basal Cell Nevus Syndrome / surgery

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649773.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


81. Kalantar DH, Belak JF, Collins GW, Colvin JD, Davies HM, Eggert JH, Germann TC, Hawreliak J, Holian BL, Kadau K, Lomdahl PS, Lorenzana HE, Meyers MA, Rosolankova K, Schneider MS, Sheppard J, Stölken JS, Wark JS: Direct observation of the alpha-epsilon transition in shock-compressed iron via nanosecond x-ray diffraction. Phys Rev Lett; 2005 Aug 12;95(7):075502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In situ x-ray diffraction studies of iron under shock conditions confirm unambiguously a phase change from the bcc (alpha) to hcp (epsilon) structure.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196791.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. El-Marakby HH: The versatile naso-labial flaps in facial reconstruction. J Egypt Natl Canc Inst; 2005 Dec;17(4):245-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin grafts can only cover superficial defects and has a natural tendency to contract and may not take properly.
  • MATERIAL AND METHODS: The study included 20 patients (12 males and 8 females) presented at the surgical department, National Cancer Institute (NCI) Cairo University with skin cancer at different areas of the face.
  • Assessment of the stage of the disease, the flap design and patient general condition.
  • Fifteen patients presented with basal cell carcinoma, 2 squamous cell carcinoma, one malignant melanoma, one keratoacanthoma, and one xeroderma pigmentosa.
  • Nasal defects constituted 75% of cases, the rest were lower eye lid (2), one upper lip and one oral commisure beside a case of cheek reconstruction.
  • There was no major complication; only one patient suffered a reactionary hemorrhage that required re-exploration to secure the bleeder.
  • The overall aesthetic results were very satisfactory in the majority of patients (16), and satisfactory in 2 cases.
  • [MeSH-major] Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102819.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


83. Mamelak AJ, Wang SQ, Goldberg LH: Linear closure for nasal defects after Mohs micrographic surgery. J Drugs Dermatol; 2009 Jan;8(1):23-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancers on the nose are very common.
  • METHODS: A retrospective analysis was conducted of 4765 patients with skin malignancies on the nose that were treated with MMS between July 1997 and January 2006.
  • The 2 major malignancies treated were basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Nose Neoplasms / surgery. Prospective Studies. Retrospective Studies. Skin Transplantation. Surgical Flaps. Young Adult

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180892.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tao H, Kitagawa N, Kako Y, Yamanaka H, Ito K, Denda K, Koyama T: A case of anorexia nervosa with Marchiafava-Bignami Disease that responded to high-dose intravenous corticosteroid administration. Psychiatry Res; 2007 Nov 15;156(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anorexia nervosa with Marchiafava-Bignami Disease that responded to high-dose intravenous corticosteroid administration.
  • We report the first known case of anorexia nervosa (AN) with Marchiafava-Bignami Disease (MBD) that responded to high-dose intravenous corticosteroid administration.
  • On admission, magnetic resonance imaging showed an area of demyelination in the splenium of the corpus callosum.
  • [MeSH-major] Anorexia Nervosa / complications. Fursultiamin / administration & dosage. Marchiafava-Bignami Disease / drug therapy. Methylprednisolone / administration & dosage. Neuroprotective Agents / administration & dosage. Vitamin B Complex / administration & dosage
  • [MeSH-minor] Adolescent. Corpus Callosum / blood supply. Corpus Callosum / drug effects. Corpus Callosum / pathology. Dose-Response Relationship, Drug. Female. Frontal Lobe / blood supply. Frontal Lobe / drug effects. Frontal Lobe / pathology. Glasgow Coma Scale. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Neurologic Examination / drug effects. Positron-Emission Tomography. Regional Blood Flow / drug effects. Temporal Lobe / blood supply. Temporal Lobe / drug effects. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Marchiafava Bignami disease.
  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933499.001).
  • [ISSN] 0165-1781
  • [Journal-full-title] Psychiatry research
  • [ISO-abbreviation] Psychiatry Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 05J61265PX / Fursultiamin; 12001-76-2 / Vitamin B Complex; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


85. Wang SQ, Dusza SW, Scope A, Braun RP, Kopf AW, Marghoob AA: Differences in dermoscopic images from nonpolarized dermoscope and polarized dermoscope influence the diagnostic accuracy and confidence level: a pilot study. Dermatol Surg; 2008 Oct;34(10):1389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective was to evaluate whether diagnosis and diagnostic confidence changes when viewing dermoscopic images from NPDs and PDs.
  • Twenty-five pigmented lesions were shown in the study, consisting of 7 seborrheic keratoses (SK), 3 basal cell carcinomas, 2 atypical nevi, 5 malignant melanomas (MM), 3 dermatofibromas, 3 blue nevi, and 2 hemangiomas.
  • CONCLUSIONS: Viewing lesions with NPD versus PD can affect the diagnosis and diagnostic confidence of physicians that are novices with dermoscopy.
  • [MeSH-major] Dermoscopy / instrumentation. Skin Diseases / diagnosis
  • [MeSH-minor] Humans. Microscopy, Polarization. Pigmentation Disorders / diagnosis. Pilot Projects. Skin Neoplasms / diagnosis


86. Saalbach A, Lange O, Nattkemper T, Meyer-Baese A: On the application of (topographic) independent and tree-dependent component analysis for the examination of DCE-MRI data. Biomed Signal Process Control; 2009 Jul;4(3):247-253
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this contribution we investigate the applicability of different methods from the field of independent component analysis (ICA) for the examination of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data from breast cancer research.
  • DCE-MRI has evolved in recent years as a powerful complement to X-ray based mammography for breast cancer diagnosis and monitoring.
  • In DCE-MRI the time related development of the signal intensity after the administration of a contrast agent can provide valuable information about tissue states and characteristics.
  • In order to evaluate the applicability of ICA, topographic ICA and tree-dependent component analysis (TCA), these methods are applied to twelve clinical cases from breast cancer research with a histopathologically confirmed diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20689662.001).
  • [ISSN] 1746-8094
  • [Journal-full-title] Biomedical signal processing and control
  • [ISO-abbreviation] Biomed Signal Process Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106799-04; United States / NCI NIH HHS / CA / K25 CA106799
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] England
  •  go-up   go-down


87. Fujino H, Saito T, Ogawa S, Kojima J: Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol; 2005 Oct;57(10):1305-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant stimulatory effect was exhibited by pitavastatin lactone, while the acid form did not exhibit ATPase hydrolysis of P-glycoprotein.
  • In the case of breast cancer resistant protein (BCRP), the acid form of pitavastatin is a substrate, whereas the lactone form is not.
  • Taking these results into consideration, several SLC and ABC transporters were identified as critical to the distribution and excretion of pitavastatin in the body.
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / metabolism. Adenosine Triphosphatases / metabolism. Animals. Carbon Radioisotopes. Dose-Response Relationship, Drug. Female. Humans. Kinetics. Neoplasm Proteins / metabolism. Oocytes / drug effects. Oocytes / metabolism. Organic Anion Transporters, Sodium-Dependent / genetics. Organic Anion Transporters, Sodium-Dependent / metabolism. Organic Anion Transporters, Sodium-Independent / genetics. Organic Anion Transporters, Sodium-Independent / metabolism. Rats. Solute Carrier Organic Anion Transporter Family Member 1B3. Solute Carrier Organic Anion Transporter Family Member 1b1 / genetics. Solute Carrier Organic Anion Transporter Family Member 1b1 / metabolism. Symporters / genetics. Symporters / metabolism. Xenopus laevis

  • MedlinePlus Health Information. consumer health - Statins.
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259759.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Carbon Radioisotopes; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Neoplasm Proteins; 0 / Organic Anion Transporters; 0 / Organic Anion Transporters, Sodium-Dependent; 0 / Organic Anion Transporters, Sodium-Independent; 0 / Quinolines; 0 / SLCO1B3 protein, human; 0 / Solute Carrier Organic Anion Transporter Family Member 1B3; 0 / Solute Carrier Organic Anion Transporter Family Member 1b1; 0 / Symporters; 145420-23-1 / sodium-bile acid cotransporter; EC 3.6.1.- / Adenosine Triphosphatases; M5681Q5F9P / pitavastatin
  •  go-up   go-down


88. Kenzaka T, Ishidoshiro A, Yamaguchi N, Tani K, Nasu M: rRNA sequence-based scanning electron microscopic detection of bacteria. Appl Environ Microbiol; 2005 Sep;71(9):5523-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SEM-ISH was applied to analyze bacterial community composition in freshwater samples, and bacterial cell counts determined by SEM-ISH with rRNA-targeted probes for major phyla within the domain Bacteria were highly correlated to those by fluorescent in situ hybridization (FISH).
  • The bacterial composition on surface of river sediment particles before and after cell dispersion treatment by sonication was successfully revealed by SEM-ISH.

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 1993;14(2):136-43 [7679962.001]
  • [Cites] Water Res. 2001 Dec;35(17):4011-8 [11791830.001]
  • [Cites] Microbiol Rev. 1995 Mar;59(1):143-69 [7535888.001]
  • [Cites] Microbiology. 1996 May;142 ( Pt 5):1097-106 [8704951.001]
  • [Cites] Histochem Cell Biol. 1996 Jul;106(1):31-9 [8858365.001]
  • [Cites] Biomaterials. 1997 Jan;18(1):81-6 [9003902.001]
  • [Cites] Arch Microbiol. 1998 Feb;169(2):136-47 [9446685.001]
  • [Cites] Appl Environ Microbiol. 1998 Apr;64(4):1536-40 [9546190.001]
  • [Cites] Microbiology. 1998 Aug;144 ( Pt 8):2085-93 [9720029.001]
  • [Cites] Eur J Histochem. 1998;42(2):111-20 [9728288.001]
  • [Cites] Lett Appl Microbiol. 1999 May;28(5):405-10 [10347897.001]
  • [Cites] Appl Environ Microbiol. 1999 Jul;65(7):3192-204 [10388721.001]
  • [Cites] Appl Environ Microbiol. 1999 Aug;65(8):3721-6 [10427073.001]
  • [Cites] FEMS Microbiol Ecol. 2004 Nov 1;50(3):203-13 [19712361.001]
  • [Cites] Appl Environ Microbiol. 2000 Apr;66(4):1692-7 [10742262.001]
  • [Cites] Appl Environ Microbiol. 2001 Jan;67(1):387-95 [11133470.001]
  • [Cites] Appl Environ Microbiol. 2002 Feb;68(2):661-7 [11823205.001]
  • [Cites] Appl Environ Microbiol. 2002 Jun;68(6):3094-101 [12039771.001]
  • [Cites] Appl Environ Microbiol. 2002 Oct;68(10):5142-50 [12324365.001]
  • [Cites] Appl Environ Microbiol. 2002 Nov;68(11):5728-36 [12406771.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):150-4 [12634782.001]
  • [Cites] J Appl Microbiol. 2003;95(1):120-8 [12807461.001]
  • [Cites] Appl Environ Microbiol. 2003 Aug;69(8):5023-8 [12902306.001]
  • [Cites] Appl Environ Microbiol. 2004 Sep;70(9):5094-101 [15345387.001]
  • [Cites] Histochem J. 1986 May;18(5):266-70 [3528066.001]
  • [Cites] Histochemistry. 1986;86(1):35-41 [2432037.001]
  • [Cites] Appl Environ Microbiol. 1990 Jun;56(6):1919-25 [2200342.001]
  • [Cites] J Electron Microsc Tech. 1991 Mar;17(3):336-43 [1646315.001]
  • [Cites] Appl Environ Microbiol. 2001 Feb;67(2):799-807 [11157246.001]
  • [Cites] PDA J Pharm Sci Technol. 2001 Mar-Apr;55(2):87-113 [11310323.001]
  • [Cites] Appl Environ Microbiol. 2001 Sep;67(9):4048-56 [11526004.001]
  • [Cites] Appl Environ Microbiol. 2002 Jan;68(1):201-10 [11772628.001]
  • [Cites] Microbiology. 2002 Jan;148(Pt 1):277-88 [11782520.001]
  • [Cites] J Appl Bacteriol. 1994 May;76(5):448-54 [8005833.001]
  • (PMID = 16151145.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotide Probes; 0 / RNA, Ribosomal; 7440-57-5 / Gold
  • [Other-IDs] NLM/ PMC1214627
  •  go-up   go-down


89. Francisco G, Neto CF, Sanches JA Jr, Ruiz IR: Genomic instability in basal cell carcinomas. J Dermatol Sci; 2005 Sep;39(3):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic instability in basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Genomic Instability / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085392.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


90. Kassem A, Pantulu D, Technau K, Kurz AK, Diaz C, Hörster S, Nashan D, Weyers W, Zur Hausen A: Merkel cell polyomavirus in naevoid basal cell carcinoma syndrome-associated basal cell carcinomas and sporadic trichoblastomas. J Dermatol Sci; 2010 Aug;59(2):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell polyomavirus in naevoid basal cell carcinoma syndrome-associated basal cell carcinomas and sporadic trichoblastomas.
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Merkel Cell / genetics. DNA, Neoplasm / genetics. DNA, Viral / genetics. Polyomavirus / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654786.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


91. Mitsuhashi M, Peel D, Ziogas A, Anton-Culver H: Enhanced Expression of Radiation-induced Leukocyte CDKN1A mRNA in Multiple Primary Breast Cancer Patients: Potential New Marker of Cancer Susceptibility. Biomark Insights; 2009 Dec 22;4:201-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced Expression of Radiation-induced Leukocyte CDKN1A mRNA in Multiple Primary Breast Cancer Patients: Potential New Marker of Cancer Susceptibility.
  • This study was designed to discover blood biomarkers of cancer susceptibility using invasive multiple (n = 21), single primary breast cancer (n = 21), and control subjects (n = 20).
  • Heparinized whole blood was incubated at 37 degrees C for 2 hours after 0-10 Gy of radiation, then cell cycle arrest marker CDKN1A and apoptosis marker BBC3 mRNA were quantified.
  • Interestingly, multiple primary cases showed higher induction of CDKN1A mRNA than single primary and control groups, whereas BBC3 did not show such differences.
  • The results suggested that cancer susceptibility represented by the multiple primary breast cancer cases was related to over-reaction of CDKN1A mRNA, not BBC3.
  • The study also suggests that ex vivo gene expression analysis could potentially be used as a new tool in epidemiological studies for cancer and radiation sensitivity research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11318-23 [11572983.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7386-91 [15123817.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):634-42 [16497944.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1317-23 [17322917.001]
  • [Cites] Pharm Res. 2008 May;25(5):1116-24 [18183479.001]
  • [Cites] Clin Chem. 2008 Apr;54(4):673-81 [18292124.001]
  • [Cites] Int J Radiat Biol. 2008 May;84(5):375-87 [18464067.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1845-51 [18493234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1236-1244 [18572087.001]
  • [Cites] Int J Radiat Biol. 2009 May;85(5):403-12 [19382019.001]
  • [Cites] Nature. 1976 Apr 1;260(5550):444-7 [1256588.001]
  • [Cites] Cell. 1992 Nov 13;71(4):587-97 [1423616.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7276-80 [1871133.001]
  • [Cites] Biotechniques. 1998 Jun;24(6):954-8, 960, 962 [9631186.001]
  • [Cites] Hum Mutat. 1999;14(1):1-8 [10447253.001]
  • [Cites] Radiat Res. 2000 Sep;154(3):342-6 [11012342.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1036-8 [14500851.001]
  • (PMID = 20072670.001).
  • [ISSN] 1177-2719
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA058860; United States / NCI NIH HHS / CA / U01 CA058860
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2805425
  • [Keywords] NOTNLM ; BBC3 / CDKN1A / DNA damage / cancer susceptibility Mitsuhashi et al / multiple primary cancer
  •  go-up   go-down


92. Wang X, Chao L, Chen L, Ma G, Jin G, Hua M, Zhou G: The mammographic correlations with Basal-like phenotype of invasive breast cancer. Acad Radiol; 2010 Mar;17(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mammographic correlations with Basal-like phenotype of invasive breast cancer.
  • RATIONALE AND OBJECTIVES: Mammography contributes to the improvement of breast carcinoma survival through early detection and treatment of breast lesions.
  • The basal-like phenotype has been found to be an independent poor prognostic factor for breast cancer.
  • The aim of this study was to determine the mammographic correlates of the basal-like phenotype of invasive breast cancer, and to more precisely predict patient outcome and those individuals who will be responsive to a specific therapeutic regimen.
  • MATERIALS AND METHODS: The mammographic findings in 267 patients with operable breast cancer were correlated with the basal-like subtype identified using immunohistochemical assessment of breast cancer cases, including estrogen receptor, progesterone receptor, HER-2/neu status, cytokeratin (CK5/6), and epidermal growth factor receptor.
  • RESULTS: Of the 267 invasive breast cancers, 40 (15%) were of the basal-like phenotype.
  • Basal-phenotype tumors were significantly more likely to manifest as a mass (P = .002), most of which were indistinct margin (P =.035), at mammography, and architecture distortion at mammography (P = .002).
  • CONCLUSION: The mammographic appearances of basal-like tumors, more mass and architecture distortion, suggest more rapid carcinogenesis.
  • Additional studies are warranted to further refine prognosis, and to optimize treatment in patients with basal-like breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiography. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiography. Mammography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic


93. Haas S, Park TW, Hahne JC, Fischer HP: Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Virchows Arch; 2008 Mar;452(3):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
  • The urokinase-type plasminogen activator (uPA) and the plasminogen activator inhibitor-1 (PAI-1) are involved in tumor invasion and metastasis as well as wound healing and inflammation.
  • We investigated the impact of tissue injury by preoperative sampling on the level of uPA/PAI-1 in paraffin tissue of 55 breast cancer cases by immunohistochemistry.
  • The tumor area surrounding the biopsy channel was compared with distant intact tumor tissue. uPA and PAI-1 were constantly expressed by the tumor cells.
  • Fibroblastic expression was higher in the tumor area surrounding the biopsy channel than in intact tissue with 47 vs 29 positive cases for uPA (p<0.001) and 35 vs 25 positive cases for PAI-1 (p=0.055).
  • A decrease in fibroblastic enzyme expression from the biopsy area to the intact tumor tissue was seen in 21 cases for uPA and 16 cases for PAI-1.
  • This difference was most evident in cases with an interval of 6 days and longer between biopsy and surgery.
  • Tissue specimen for ELISA analysis should not be taken from the tumor area around the biopsy channel in the resection specimen.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Plasminogen Activator Inhibitor 1 / biosynthesis. Urokinase-Type Plasminogen Activator / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4065-71 [8033138.001]
  • [Cites] Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22 [1515091.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4525-30 [9788594.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6827-9 [2119883.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):359-65 [8434636.001]
  • [Cites] Histopathology. 2006 May;48(6):692-701 [16681685.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1485-501 [11706057.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 May;376(5):259-67 [7662168.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1269-80 [8203466.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 16;94(2):116-28 [11792750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):75-9 [2296606.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1434-41 [9836475.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1534-41 [10188903.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4617-22 [12183417.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1219-27 [11021826.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):913-20 [11416112.001]
  • (PMID = 18196271.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Plasminogen Activator Inhibitor 1; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


94. Crump RC, Adams HE, Hobbie JE, Kling GW: Biogeography of bacterioplankton in lakes and streams of an Arctic tundra catchment. Ecology; 2007 Jun;88(6):1365-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biogeography of bacterioplankton in lakes and streams of an Arctic tundra catchment.
  • Bacterioplankton community composition was compared across 10 lakes and 14 streams within the catchment of Toolik Lake, a tundra lake in Arctic Alaska, during seven surveys conducted over three years using denaturing gradient gel electrophoresis (DGGE) of PCR-amplified rDNA.
  • Bacterioplankton communities in streams draining tundra were very different than those in streams draining lakes.
  • Communities in streams draining lakes were similar to communities in lakes.
  • In a connected series of lakes and streams, the stream communities changed with distance from the upstream lake and with changes in water chemistry, suggesting inoculation and dilution with bacteria from soil waters or hyporheic zones.
  • In the same system, lakes shared similar bacterioplankton communities (78% similar) that shifted gradually down the catchment.
  • In contrast, unconnected lakes contained somewhat different communities (67% similar).
  • We found evidence that dispersal influences bacterioplankton communities via advection and dilution (mass effects) in streams, and via inoculation and subsequent growth in lakes.
  • The spatial pattern of bacterioplankton community composition was strongly influenced by interactions among soil water, stream, and lake environments.
  • Our results reveal large differences in lake-specific and stream-specific bacterial community composition over restricted spatial scales (<10 km) and suggest that geographic distance and connectivity influence the distribution of bacterioplankton communities across a landscape.
  • [MeSH-major] Bacteria / growth & development. Biodiversity. Fresh Water / microbiology. Plankton / growth & development. Water Microbiology
  • [MeSH-minor] Arctic Regions. DNA, Bacterial / analysis. DNA, Ribosomal Spacer. Ecosystem. Electrophoresis, Polyacrylamide Gel. Polymerase Chain Reaction. Population Dynamics. Rivers / microbiology. Water Movements

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601129.001).
  • [ISSN] 0012-9658
  • [Journal-full-title] Ecology
  • [ISO-abbreviation] Ecology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


95. Yamamoto F, Yamamoto M: Scanning copy number and gene expression on the 18q21-qter chromosomal region by the systematic multiplex PCR and reverse transcription-PCR methods. Electrophoresis; 2007 Jun;28(12):1882-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined differences in copy number and expression of 127 genes located on the 18q21-qter chromosomal region of the breast and prostate cancer cell lines, using the systematic multiplex PCR and reverse transcription-PCR (SM PCR and SM RT-PCR) methods that we developed.
  • In the chromosomal region where losses are frequent in breast, prostate, and other cancers, we detected a homozygous deletion of the SMAD4 gene in the MDA-MB-468 breast cancer cell line.
  • We also observed partial or entire loss of expression in genes such as CCBE1, CCDC11, CD226, NP_115536.1, NP_689683.2, RNF152, SERPINB8, and TCF4 in certain breast and/or prostate cancer cell lines.
  • An increase in gene expression was rare, but found with the transcription factor ONECUT2 gene in all of the cancer cell lines examined.
  • Further analysis of clinical specimens of breast cancer by real-time qRT-PCR demonstrated that the gene expression of CCBE1, TCF4, NP_115536.1, and NP_689683.2 was downregulated in the majority of clinical cases of breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal / genetics. Chromosomes, Human, Pair 18 / genetics. Gene Dosage. Gene Expression. Prostatic Neoplasms / genetics
  • [MeSH-minor] Cell Line. DNA Primers. Female. Gene Amplification / genetics. Gene Deletion. Gene Expression Profiling. Humans. Male. Oligonucleotide Array Sequence Analysis / methods. Polymerase Chain Reaction / methods. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523142.001).
  • [ISSN] 0173-0835
  • [Journal-full-title] Electrophoresis
  • [ISO-abbreviation] Electrophoresis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA087069
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


96. Anderson WF, Matsuno RK, Sherman ME, Lissowska J, Gail MH, Brinton LA, Yang XR, Peplonska B, Chen BE, Rosenberg PS, Chatterjee N, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Devesa SS, García-Closas M: Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control; 2007 May;18(4):439-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions.
  • OBJECTIVE: Clarifying age-specific female breast cancer risks and interactions may provide important etiologic clues.
  • METHOD: Using a population-based case-control study in Poland (2000-2003) of 2,386 incident breast cancer cases and 2,502 control subjects aged 25-74 years, we estimated age-specific breast cancer incidence rates according to risk factors.
  • RESULTS: Breast cancer risks were elevated among women with positive family history (FH), younger age at menarche, older age at first full-term birth, nulliparity, exogenous hormonal usage, and reduced physical activity (PA).
  • For example, nulliparity compared to parity reduced breast cancer risk among women ages 25-39 years then rates crossed or reversed, after which nulliparity increased relative risks among women ages 40-74 years.
  • If confirmed in other populations, qualitative interactions for a continuous covariate such as age will be difficult to reconcile in a sequential (multistep or monolithic) 'stochastic' breast cancer model.
  • Alternatively, the reversal of relative risks among younger and older women suggests subgroup heterogeneity with different etiologic mechanisms for early-onset and late-onset breast cancer types.
  • [MeSH-major] Breast Neoplasms / epidemiology. Risk Assessment / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Body Mass Index. Case-Control Studies. Female. Hormone Replacement Therapy / utilization. Humans. Incidence. Middle Aged. Motor Activity. Poland / epidemiology. Risk. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216325.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


97. Mao X, Hamoudi RA, Zhao P, Baudis M: Genetic losses in breast cancer: toward an integrated molecular cytogenetic map. Cancer Genet Cytogenet; 2005 Jul 15;160(2):141-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic losses in breast cancer: toward an integrated molecular cytogenetic map.
  • Breast cancer is the most common malignant disease in Caucasian women, but is less frequent in Chinese women.
  • The molecular basis for such ethnical difference in disease pathogenesis remains unknown.
  • To address this issue, we performed allelotyping analysis of formalin-fixed, paraffin-embedded samples from 21 Chinese patients with breast cancer using 59 fluorescently tagged oligonucleotide primers amplifying microsatellite loci.
  • Loss of heterozygosity (LOH) was found in all tumor samples.
  • To compare our data to previous reports, we determined the band-specific frequency of chromosomal imbalances in breast cancer karyotypes reported in the Mitelman database, and from the CGH results of cases accessible through the Progenetix website.
  • Furthermore, published LOH analyses of breast cancer cases were compared to our own LOH results, demonstrating the most common chromosomal regions affected by allelic losses.
  • The combined results provide a comprehensive view of genetic losses in breast cancers, indicating the comparability of these different techniques and suggesting the presence of a distinct subset of breast cancers with high-frequency LOH at chromosomes 1 and 2p in Chinese patients.
  • [MeSH-major] Breast Neoplasms / genetics. Cytogenetic Analysis. Loss of Heterozygosity / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993270.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Jovanov-Milosević N, Culjat M, Kostović I: Growth of the human corpus callosum: modular and laminar morphogenetic zones. Front Neuroanat; 2009;3:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of the human corpus callosum: modular and laminar morphogenetic zones.
  • The purpose of this focused review is to present and discuss recent data on the changing organization of cerebral midline structures that support the growth and development of the largest commissure in humans, the corpus callosum.
  • We will put an emphasis on the callosal growth during the period between 20 and 45 postconceptual weeks (PCW) and focus on the advantages of a correlated histological/magnetic resonance imaging (MRI) approach.
  • The midline structures that mediate development of the corpus callosum in rodents, also mediate its early growth in humans.
  • Postmortem MRI at 3 T can demonstrate transient structures based on higher water content in ECM, and give us the possibility to follow the growth of the corpus callosum in vivo, due to the characteristic MR signal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2003 Nov 7;302(5647):1044-6 [14605369.001]
  • [Cites] Prog Mol Subcell Biol. 2003;32:1-32 [12827969.001]
  • [Cites] Glia. 2003 Jan 15;41(2):117-27 [12509802.001]
  • [Cites] Cereb Cortex. 2002 May;12(5):536-44 [11950771.001]
  • [Cites] J Comp Neurol. 2001 May 28;434(2):147-57 [11331522.001]
  • [Cites] J Neurosci. 2001 Apr 15;21(8):2749-58 [11306627.001]
  • [Cites] Cereb Cortex. 2000 Dec;10(12):1200-10 [11073869.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1293-326 [10869045.001]
  • [Cites] Cereb Cortex. 2009 Jul;19 Suppl 1:i11-21 [19357391.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4263-73 [19339620.001]
  • [Cites] Curr Top Dev Biol. 2005;69:267-346 [16243603.001]
  • [Cites] Mol Cell Neurosci. 2005 May;29(1):40-55 [15866045.001]
  • [Cites] J Comp Neurol. 2005 Mar 21;483(4):375-82 [15700272.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):685-98 [15632069.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1653-7 [10335784.001]
  • [Cites] Development. 1998 Dec;125(24):5043-53 [9811588.001]
  • [Cites] J Comp Neurol. 1998 Oct 19;400(2):197-206 [9766399.001]
  • [Cites] J Comp Neurol. 1995 May 15;355(4):615-28 [7636035.001]
  • [Cites] J Neurosci. 1994 Jun;14(6):3500-10 [8207468.001]
  • [Cites] J Comp Neurol. 1993 Feb 15;328(3):415-36 [8440789.001]
  • [Cites] J Comp Neurol. 1992 Sep 1;323(1):81-90 [1430316.001]
  • [Cites] J Comp Neurol. 1991 May 1;307(1):144-62 [1713225.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1354-8 [1705036.001]
  • [Cites] J Comp Neurol. 1988 May 15;271(3):355-86 [2454966.001]
  • [Cites] J Comp Neurol. 1988 Jun 1;272(1):68-89 [2454978.001]
  • [Cites] Brain. 1989 Jun;112 ( Pt 3):799-835 [2731030.001]
  • [Cites] J Comp Neurol. 1989 Feb 8;280(2):213-30 [2925893.001]
  • [Cites] J Comp Neurol. 1986 Feb 15;244(3):331-48 [3958231.001]
  • [Cites] J Comp Neurol. 1968 Jan;132(1):45-72 [5293999.001]
  • [Cites] J Comp Neurol. 1990 Jul 15;297(3):441-70 [2398142.001]
  • [Cites] Clin Perinatol. 1990 Mar;17(1):83-102 [2318019.001]
  • [Cites] Science. 1983 Jun 3;220(4601):1067-9 [6844928.001]
  • [Cites] J Comp Neurol. 1982 Sep 1;210(1):10-29 [7130467.001]
  • [Cites] Brain Res. 1971 Sep 10;32(1):31-43 [5000193.001]
  • [Cites] Clin Genet. 2004 Oct;66(4):276-89 [15355427.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):2080-9 [15289268.001]
  • [Cites] Biol Psychiatry. 2004 Jul 15;56(2):80-5 [15231439.001]
  • [Cites] Neuroimage. 2004 Jul;22(3):1302-14 [15219602.001]
  • [Cites] J Comp Neurol. 2004 Jan 6;468(2):217-32 [14648681.001]
  • [Cites] J Comp Neurol. 2009 May 20;514(3):215-25 [19296474.001]
  • [Cites] Brain. 2008 Dec;131(Pt 12):3201-8 [18952670.001]
  • [Cites] Dev Biol. 2008 Nov 15;323(2):143-51 [18801355.001]
  • [Cites] Neuroimage. 2008 Nov 1;43(2):213-24 [18694838.001]
  • [Cites] Adv Exp Med Biol. 2007;600:73-89 [17607948.001]
  • [Cites] Eur J Neurosci. 2007 Mar;25(5):1384-94 [17425565.001]
  • [Cites] Nat Rev Neurosci. 2007 Apr;8(4):287-99 [17375041.001]
  • [Cites] Cereb Cortex. 2007 Mar;17(3):531-41 [16627861.001]
  • [Cites] Curr Opin Neurobiol. 2007 Feb;17(1):3-14 [17275286.001]
  • [Cites] Semin Fetal Neonatal Med. 2006 Dec;11(6):415-22 [16962836.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):27-38 [16905335.001]
  • [Cites] Coll Antropol. 2006 Jun;30(2):375-81 [16848154.001]
  • [Cites] Eur J Radiol. 2006 Feb;57(2):187-98 [16439088.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):471-81 [16458080.001]
  • [Cites] Nat Neurosci. 2006 Jun;9(6):787-97 [16715082.001]
  • [Cites] J Neurosci. 2006 May 24;26(21):5840-8 [16723543.001]
  • [Cites] Development. 2006 Jun;133(11):2243-52 [16690755.001]
  • [Cites] J Neurosci. 2006 Apr 5;26(14):3829-39 [16597737.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2006 Feb;288(2):191-204 [16411247.001]
  • [Cites] J Comp Neurol. 2005 Oct 17;491(2):109-22 [16127688.001]
  • [Cites] Dev Biol. 2006 Jan 1;289(1):141-51 [16309667.001]
  • [Cites] Nat Rev Neurosci. 2005 Dec;6(12):955-65 [16288299.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2671-84 [16286422.001]
  • (PMID = 19562029.001).
  • [ISSN] 1662-5129
  • [Journal-full-title] Frontiers in neuroanatomy
  • [ISO-abbreviation] Front Neuroanat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC2697006
  • [Keywords] NOTNLM ; callosal septa / fetal brain / glia of indusium griseum / magnetic resonance imaging / midline structures / semaphorin3A
  •  go-up   go-down


99. Milleret C, Buser P, Watroba L: Unilateral paralytic strabismus in the adult cat induces plastic changes in interocular disparity along the visual midline: contribution of the corpus callosum. Vis Neurosci; 2005 May-Jun;22(3):325-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral paralytic strabismus in the adult cat induces plastic changes in interocular disparity along the visual midline: contribution of the corpus callosum.
  • Neurones activated through the corpus callosum (CC) in the cat visual cortex are known to be almost entirely located at the 17/18 border.
  • On the other hand, strabismus induced a loss of orientation selectivity regardless of whether neurones were activated directly or through the CC.
  • [MeSH-major] Corpus Callosum / physiopathology. Functional Laterality / physiology. Neuronal Plasticity / physiology. Strabismus / physiopathology. Vision Disparity / physiology. Visual Fields / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079008.001).
  • [ISSN] 0952-5238
  • [Journal-full-title] Visual neuroscience
  • [ISO-abbreviation] Vis. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Pfefferbaum A, Adalsteinsson E, Sullivan EV: Dysmorphology and microstructural degradation of the corpus callosum: Interaction of age and alcoholism. Neurobiol Aging; 2006 Jul;27(7):994-1009
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysmorphology and microstructural degradation of the corpus callosum: Interaction of age and alcoholism.
  • To quantify the potential compounded effect of age and alcoholism, we used conventional structural MRI and diffusion tensor imaging (DTI) to examine the macrostructural and microstructural integrity of the corpus callosum, one of the most prominent white matter structures of the brain, in 131 adults, age 27-75 years.
  • Compared with the 74 controls, the 40 alcoholic men and 17 alcoholic women, who were abstinent from alcohol for an average of 3 months, showed similar patterns and extents of callosal shrinkage, which was greatest in the genu and body and less prominent in the splenium.
  • [MeSH-major] Aging / pathology. Alcohol-Induced Disorders, Nervous System / pathology. Alcoholism / pathology. Corpus Callosum / drug effects. Corpus Callosum / pathology. Ethanol / adverse effects
  • [MeSH-minor] Adult. Age Factors. Aged. Anisotropy. Body Water / drug effects. Body Water / physiology. Brain Mapping. Diffusion / drug effects. Diffusion Magnetic Resonance Imaging. Female. Gait Disorders, Neurologic / chemically induced. Gait Disorders, Neurologic / pathology. Gait Disorders, Neurologic / physiopathology. Humans. Male. Memory Disorders / chemically induced. Memory Disorders / pathology. Memory Disorders / physiopathology. Middle Aged. Myelin Sheath / drug effects. Myelin Sheath / pathology. Nerve Fibers, Myelinated / drug effects. Nerve Fibers, Myelinated / pathology. Predictive Value of Tests. Wallerian Degeneration / chemically induced. Wallerian Degeneration / pathology. Wallerian Degeneration / physiopathology

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964101.001).
  • [ISSN] 0197-4580
  • [Journal-full-title] Neurobiology of aging
  • [ISO-abbreviation] Neurobiol. Aging
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG17919; United States / NIAAA NIH HHS / AA / R01 AA012388; United States / NIAAA NIH HHS / AA / AA05965; United States / NIAAA NIH HHS / AA / AA 10723; United States / NIAAA NIH HHS / AA / AA 12388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down






Advertisement